Exhibit 10.03

 

CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN
OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND, WHERE APPLICABLE,
HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE
CONFIDENTIAL MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION

 

CONFIDENTIAL

Amended & Restated IP License Agreement

 

 

 

This Amended & Restated IP License Agreement (the “License Agreement”) is made
and entered into effective as of July 19, 2016 (the “Effective Date”) by and
between Amyris, Inc., a Delaware corporation, having its place of business at
5885 Hollis Street, Suite 100, Emeryville, California 94608 (“Amyris”) and Novvi
LLC, a Delaware limited liability corporation, having its place of business at
5885 Hollis Street, Suite 100, Emeryville, California 94608 (“Novvi LLC”).
Amyris and Novvi LLC are sometimes referred to herein individually as a “Party”
and collectively as the “Parties.”

 

WHEREAS, Amyris and Cosan US, Inc. formed Novvi LLC on September 6, 2011, with
each owning fifty percent (50%) of the membership units of Novvi LLC, to operate
a joint venture involving the development, production, marketing and sale of
Base Oils (as defined below), Additives (as defined below), and Lubricants (as
defined below) for use in the Lubricants Markets (as defined below);

 

WHEREAS, on March 26, 2013, Amyris and Cosan US executed an Amended and Restated
Operating Agreement for Novvi LLC (“Amended and Restated Operating Agreement”)
to memorialize their respective initial capital contributions to Novvi LLC and
to establish how they will operate Novvi LLC;

 

WHEREAS, in order to fulfill its initial capital contribution to Novvi LLC under
the Amended and Restated Operating Agreement and to enable Novvi LLC to fulfill
its intended purpose to develop, produce, market, and sell Base Oils, Additives,
and Lubricants, Amyris and Novvi LLC executed an IP License Agreement (the
“Original License Agreement”) under which Amyris agreed to license Novvi LLC
rights under certain of its intellectual property;

 

WHEREAS, the Parties amended certain portions of the Original License Agreement
on March 21, 2016 through an amendment #1 to the Original License Agreement;

 

WHEREAS, on July 19, 2016, due to the addition of American Refining Group, Inc.
as a new member of Novvi LLC, Amyris and Cosan US amended and restated the
Amended and Restated Operating Agreement (as such document may be further
amended from time-to-time, the “Second Amended and Restated Operating
Agreement”);

 

WHEREAS, in conjunction with the execution of the Second Amended and Restated
Operating Agreement, the Parties desire to further amend and restate the
Original License Agreement through their execution of this License Agreement;
and

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants contained in this License Agreement, the Parties hereby agree as
follows:

 

ARTICLE 1

 

DEFINITIONS

 

Terms defined in this Article 1 and parenthetically elsewhere, including the
introductory paragraph and the recitals, will have the same meaning throughout
this License Agreement unless otherwise specified.

 

“Additive” means any material added to a Base Oil to change its properties,
characteristics, or performance (e.g., anti-foam, anti-wear, corrosion
inhibitor, detergent, dispersant, pour point depressant, anti-oxidant, viscosity
index improver, or friction modifier).

Page 1 of 37

CONFIDENTIAL

“Affiliate” means, with regard to a particular entity (a “First Person”), any
person or entity who, directly or indirectly, through one or more intermediates,
Controls the First Person, is Controlled by the First Person, or is under common
Control with the First Person. Notwithstanding the preceding definition, for
purposes of this License Agreement, Novvi LLC is not considered an Affiliate of
Amyris or Cosan US (or their respective Affiliates) nor are Amyris and Cosan US
(or their respective Affiliates) considered Affiliates of Novvi LLC.

 

“Alternative Technology” means a technology (other than a BioFene-related
technology) from a renewable source or a molecule (other than a BioFene-derived
molecule) from a renewable source from which Base Oils or Additives, in each
case, for the Lubricants Market could reasonably be expected to be developed or
made.

 

“Amyris Base Technology” means the Patents and Know-How that (i) are Controlled
by Amyris as of the Effective Date or become Controlled by Amyris during the
term of Novvi LLC’s licenses under Section 2.1 and (ii) are necessary or
reasonably useful for the development, making (and having made), offering for
sale, sale, and importing of Base Oils, Additives, and Lubricants derived from
BioFene. For the avoidance of doubt, the term “Amyris Base Technology” expressly
excludes any Amyris BioFene Manufacturing Technology.

 

“Amyris BioFene Manufacturing Technology” means the Patents and Know-How that
(i) are Controlled by Amyris and (ii) are necessary or reasonably useful for the
development, making (and having made), offering for sale, sale, and importing of
BioFene itself, including, but not limited to, the escrowed BioFene Production
Strain and any Patents and Know-How related to the genetic engineering of such
BioFene Production Strain, the fermentation methods for making BioFene, the
methods of recovery of BioFene from fermentation broth, the processes of
isolating BioFene directly from fermentation broth, and the methods of purifying
BioFene. The term “Amyris BioFene Manufacturing Technology” also includes any
and all Joint BioFene Manufacturing Improvements and Novvi LLC BioFene
Manufacturing Improvements, but expressly excludes any Novvi LLC BioFene
Transformation Technology

 

“Amyris Breach Invention” means any and all inventions, discoveries, data, and
information, whether or not copyrightable or patentable, conceived, reduced to
practice, made, observed or developed (together with all intellectual property
rights related thereto) by or on behalf of Amyris or its Affiliates or
sublicensees, solely or jointly with others, in violation of the license granted
to it in Section 2.2.

 

"Amyris Invention" means any and all inventions, discoveries, data, and
information, whether or not copyrightable or patentable, conceived, reduced to
practice, made, observed or developed (together with all intellectual property
rights related thereto) by or on behalf of Amyris, solely or jointly with
others. The term “Amyris Invention” includes any improvement by or on behalf of
Amyris, solely or jointly with others, during the term of Amyris’s license under
Section 2.2 to Novvi LLC BioFene Transformation Technology, but excludes Amyris
Breach Inventions.

 

“Amyris Pre-Signature Base Technology” means Amyris Base Technology used by
Amyris or an Amyris Affiliate to produce Base Oils or Lubricants offered for
sale, sold, or sampled to Third Parties before the Effective Date.

 

“Applicable Law” means any law, rule, treaty, or regulation of any governmental
authority or any judgment, order, write, decree, permit or license of any
governmental authority of competent jurisdiction, in each case applicable to the
Party or activity at issue.

Page 2 of 37

CONFIDENTIAL

“Base Oil” means a fluid base compound to which other oils, Additives, or
components are added to produce a Lubricant.

 

“BioFene” means farnesene produced through Amyris BioFene Manufacturing
Technology.

 

“By-Products” means those by-products directly resulting from (1) Novvi LLC’s
manufacture, under its license in Section 2.1(a)(i), of Base Oils, Additives, or
Lubricants derived from BioFene solely for the Lubricants Market or (2) the
manufacture of Base Oils, Additives, or Lubricants derived from BioFene solely
for the Lubricants Market by a permitted sublicensee of Novvi LLC per a
sublicense under Sections 2.1(b) or (c). For clarity, Diesel By-Products are a
subset of By-Products.

 

“Copyrights” means all copyrights, whether in published or unpublished works;
databases, data collections and rights therein, mask work rights, software, web
site content; rights to compilations, collective works and derivative works of
any of the foregoing and moral rights in any of the foregoing; registrations and
applications for registration for any of the foregoing and any renewals or
extensions thereof; and moral rights and economic rights of others in any of the
foregoing.

 

“Control” (including any variations such as “Controls, “Controlled” or
“Controlling”) means:

 

(i)in the context of Patents and Know-How, rights under and to such Patents and
Know-How held by a Party, whether by ownership or license, sufficient to grant
the applicable license or rights under this License Agreement without violating
the terms of any arrangement with any Third Party; and

 

(ii)in the definition of Affiliate, (1) possessing, directly or indirectly, the
power to direct the management or policies, whether through the ownership of
voting securities, by contract relating to voting rights or corporate
governance, or otherwise, or (2) ownership, directly or indirectly, of more than
fifty percent (50%) of the voting securities or other ownership interest.

 

“Escrow Agreement” means the Strain Escrow Agreement, dated July 19, 2016, by
and between Amyris, Novvi LLC, and SciSafe Inc., as may be amended from
time-to-time.

 

“European Union” means those countries that were members of the European Union
as March 21, 2016, which countries are listed on Exhibit A to this Agreement.”

 

“Exclusivity Exceptions” means the rights retained by Amyris under Amyris Base
Technology for (i) itself and its Affiliates working independently or together,
(ii) Total working independently, and (iii) Total and Amyris (and/or Amyris
Affiliates) working together, to develop, make (and have made), offer for sale,
sell, and import Base Oils derived from BioFene for use in the Lubricants Market
but only to the extent such Base Oils are used as a component in such entities’
own Lubricants in such market. For clarity, Total, Amyris and/or Amyris
Affiliates have no retained rights under Amyris Base Technology to develop, make
(have made), offer for sale, sell, or import any Base Oil derived from BioFene
for use in the Lubricants Market as a product separate and apart from a finished
Lubricant.

 

“Exploit” means to make, have made, import, use, sell, have sold, distribute,
dispose of or offer to dispose of, market, promote or offer for sale including
to research and develop.

Page 3 of 37

CONFIDENTIAL

“Insolvency Event” means:

 

(i)an involuntary petition under any bankruptcy or insolvency law or under the
reorganization provisions of any such law is filed with respect to a Party or a
receiver of, or for, the property of a Party is appointed without acquiescence
or consent of such Party, which petition or appointment remains undischarged or
unstayed for an aggregate period of ninety (90) days (whether or not
consecutive); or

 

(ii)a Party consents to the entry of an order for relief against it in an
involuntary case under any bankruptcy or insolvency law or under the
reorganization provisions of any such law; or

 

(iii)a voluntary petition under any bankruptcy or insolvency law or under the
reorganization provisions of any such law is filed by a Party, a voluntary
assignment of a Party’s property for the benefit of creditors is made, or a
receiver of, or for, the property of a Party is appointed by, or acquiesced or
consented to, by such Party.

 

“Joint BioFene Manufacturing Improvements” means any and all inventions,
discoveries, data, and information, whether or not copyrightable or patentable,
conceived, reduced to practice, made, observed or developed (together with all
intellectual property rights related thereto) jointly by or on behalf of Amyris
and Novvi LLC (or their respective Affiliates, employees, sublicensees,
contractors, or agents) that are based upon, derived from, incorporating, in
connection with or related to Amyris BioFene Manufacturing Technology, including
in connection with the conversion or operation of a sugar/ethanol mill to
include the manufacture of BioFene or the operation of such mill or facility in
connection with Novvi LLC’s manufacture of BioFene.

 

“Joint Invention” means any and all inventions, discoveries, data, and
information, whether or not copyrightable or patentable, conceived, reduced to
practice, made, observed or developed (together with all intellectual property
rights related thereto) jointly by or on behalf of Amyris and Novvi LLC (or
their respective Affiliates, employees, sublicensees, contractors, or agents)
during the term of this License Agreement, other than Joint BioFene
Manufacturing Improvements.

 

“Know-How” means any non-patented information and tangible materials, including:
(i) technical and non-technical data, specifications, formulae, compounds,
formulations, assays, designs, results, information, conclusions,
interpretations, inventions, developments, discoveries, ideas, improvements, and
trade secrets, (ii) methods, databases, tests, procedures, processes, and
techniques, (iii) escrowed Production Strains (if applicable), and (iv) other
know-how and technology including Copyrights.

 

“Lubricant” means all substances introduced between two moving surfaces to
reduce the friction between them, improving efficiency and reducing wear, or
dissolving or transporting foreign particles, or distributing heat, in each case
comprising a formulation of at least one Base Oil combined or blended with
Additives, sold as a finished product for automotive and industrial
applications, for use in, by way of example only: automotive, 2-cycle, marine
and other engines, ship lubrication, hydraulic equipment, food processing
equipment and machinery, and wind turbines. However, the term “Lubricants”
expressly excludes drilling oils, fluids and muds, in accordance with the
standards set by American Petroleum Institute.

 

“Lubricants Market” means the worldwide market for automotive, commercial, and
industrial Lubricants. For the avoidance of doubt, the following markets, but
not limited to the following markets, are expressly excluded from the term
“Lubricants Market”: the markets for flavors and fragrances, food additives,
cosmetics and personal care, drilling oils, fluids and muds, fuels, cleaners,
paints, coatings, ink,

Page 4 of 37

CONFIDENTIAL

consumer-packaged goods, pesticides, and pharmaceuticals.

 

“Novvi LLC BioFene Transformation Technology” means the Patents and Know-How in
each case that (i) are Controlled by Novvi LLC as of the Effective Date or
become Controlled by Novvi LLC during the term of Amyris’s license under Section
2.2 (in each case other than Patents and Know-How licensed from Amyris) and (ii)
are related to the chemical transformation of BioFene or a BioFene-derivative
into another compound. For clarity, the term “Novvi LLC BioFene Transformation
Technology” does not include Novvi LLC Breach Inventions.

 

"Novvi LLC BioFene Manufacturing Improvement" means any and all inventions,
discoveries, data, and information, whether or not copyrightable or patentable,
conceived, reduced to practice, made, observed or developed (together with all
intellectual property rights related thereto) by or on behalf of Novvi LLC or
its Affiliates or sublicensees, solely or jointly with others that are based
upon, derived from, incorporating, in connection with or related to Amyris
BioFene Manufacturing Technology.

 

“Novvi LLC Breach Invention” means any and all inventions, discoveries, data,
and information, whether or not copyrightable or patentable, conceived, reduced
to practice, made, observed or developed (together with all intellectual
property rights related thereto) by or on behalf of Novvi LLC or its Affiliates
or sublicensees, solely or jointly with others, in violation of the licenses
granted to it in Sections 2.1 or 2.3.

 

"Novvi LLC Invention" means any and all inventions, discoveries, data, and
information, whether or not copyrightable or patentable, conceived, reduced to
practice, made, observed or developed (together with all intellectual property
rights related thereto) by or on behalf of Novvi LLC, solely or jointly with
others. The term “Novvi LLC Invention” includes any improvement by or on behalf
of Novvi LLC, solely or jointly with others, during the term of Novvi LLC’s
licenses under Section 2.1 to Amyris Base Technology, but excludes Novvi LLC
Breach Inventions and any Novvi LLC BioFene Manufacturing Improvements or Joint
BioFene Manufacturing Improvements.

 

“Patents” means any patents, patent applications, or certificates of invention,
together with all additions, divisions, continuations, continuations-in-part,
provisionals, converted provisionals, substitutions, reissues, re-examinations,
revalidations, extensions, registrations, patent term extensions, supplemental
protection certificates, renewals, and the like with respect to any of the
foregoing.

 

“Production Strain” means a recombinant yeast or some other microbial agent that
has been genetically engineered to make a desired compound or product by means
of a fermentation process. For clarity, the term Production Strain encompasses
populations, subpopulations, and derivatives of such genetically engineered
yeast or other microbial agent.

 

“Third Party” means any person, corporation, joint venture or other entity,
other than Novvi LLC, Amyris, Cosan US, their respective Affiliates, or their
respective permitted successors and assigns.

 

“Total” means Total Gas & Power USA, SAS, a société par acions simplifiée
organized under the laws of the Republic of France, and its Affiliates.

 

The following terms have the meanings set forth in the Section set forth
opposite such term.

 

Term Section     Amended and Restated Operating Agreement Recitals Amyris
Introductory paragraph

 

 

Page 5 of 37

CONFIDENTIAL

Amyris Designate 5.9(a) Amyris Indemnitees 7.2 Amyris Third Party Claim 7.2
Arbitral Tribunal 8.2(c) Arbitration Chamber 8.2(b) Arbitration Rules 8.2(b)
Assumption Notice 7.3(b) Code 2.6 Confidential Information 5.10(a) Diesel
By-Products 4.1 Disclosing Party 5.10(a) Effective Date Introductory paragraph
Escrow Agent 2.3(c) Escrowed Materials 2.3(c) Exercise Notice 3.3(a)
Indemnification Claim Notice 7.3(a) Indemnified Party 7.3(a) Indemnifying Party
7.3(a) Jet Fuel By-Product 4.2(a) License Agreement Introductory paragraph
License Conversion Event 2.3(b) Losses 7.1 Novvi LLC Introductory paragraph
Novvi LLC Designate 5.9(b) Novvi LLC Indemnitees 7.1 Novvi LLC Third Party Claim
7.1 Original License Agreement Recitals Parties Introductory paragraph Party
Introductory paragraph Receiving Party 5.10(a) Representative 5.10(a) ROFO 3.1
ROFO Notice 3.2 Second Amended and Restated Operating Agreement Recitals
Selected Arbitration 8.2(h) SOPs 2.3(c) Third Party Claim 7.3(a)

 

ARTICLE 2

 

LICENSE GRANTS

 

2.1 Licenses to Novvi LLC under Amyris Base Technology.

 

(a) Licenses to Make Base Oils, Additives, and Lubricants from BioFene. Subject
to the terms and conditions in this License Agreement, Amyris hereby grants
Novvi LLC:

 

(i)an exclusive (except as to the rights retained in the scope of the
Exclusivity Exceptions), worldwide, royalty-free, non-sublicensable (except as
set forth in Subsections (b) and (c) below), and non-assignable license under
Amyris Base Technology to Exploit Base Oils, Additives (other than viscosity
index improvers), and Lubricants derived from BioFene

 

Page 6 of 37

CONFIDENTIAL

solely for the Lubricants Market and, as described below in this Section 2.1(a),
for such customers outside the Lubricants Market for whom Amyris grants a
waiver; and

 

(ii)subject to the limitations in Article 4 restricting the sale of By-Products
for use in or as (i) diesel fuel in the European Union and (ii) jet fuel
worldwide, a non-exclusive, worldwide, royalty-free, non-sublicensable, and
non-assignable license under Amyris Base Technology to offer for sale, sell, and
import any By-Products

 

(iii)a non-exclusive, worldwide, royalty-free, non-sublicensable (except as set
forth in Subsections (b) and (c) below), and non-assignable license under Amyris
Base Technology to Exploit Additives that are viscosity index improvers derived
from BioFene solely for the Lubricants Market.

 

Consistent with the scope of its licenses in (a)(i) and (iii), Novvi LLC and its
Affiliates shall not sell any Base Oil, Additive, or Lubricant derived from
BioFene to any Third Party that Novvi LLC or its Affiliates knows has previously
resold or used, or intends to resell or use, such product outside of the
Lubricants Market, and Amyris acknowledges that Novvi LLC and its Affiliates
will not be responsible for any resale or use of a Novvi LLC or Novvi LLC
Affiliate’s Base Oil, Additive, or Lubricant derived from BioFene outside of the
Lubricants Market by any Third Party whom Novvi LLC or its Affiliates did not
know had previously resold or used, or intended to resell or use, such product
outside of the Lubricants Market.

 

If Novvi LLC or its Affiliate identify an opportunity to sell Base Oil derived
from BioFene outside of the Lubricants Market to a potential customer that is
currently using a Base Oil composed of any combinations of Base Oil Groups I-IV
as defined by the American Petroleum Institute, Novvi LLC will provide written
notice to Amyris of the opportunity and state the rationale for seeking a waiver
to the scope of the license in Section 2.1(a)(i) regarding such opportunity. 
Amyris will promptly consider such waiver request in good faith and not
unreasonably withhold its approval of such request. However, if Amyris has
licensed such opportunity to a Third Party or has an ongoing business
relationship with such prospective customer as of the date of such notice, then
declining to grant such waiver will never be considered unreasonable. If Amyris
approves a waiver, it must be in writing to be effective, and then the sale of
Base Oil derived from BioFene by Novvi LLC to such potential customer for such
approved use, and future sales to such potential customer for such approved use,
will not be a breach of its license hereunder, subject to compliance with the
preceding paragraph regarding knowledge of such customer’s previous or intended
use or resale of the products outside such approved use or the Lubricants
Market.

 

(b) Sublicense Rights to Affiliates. Novvi LLC may sublicense its rights under
the licenses granted in Subsections (a)(i) and (iii) to an Affiliate of Novvi
LLC; provided, that,:

 

(i)Novvi LLC shall grant such sublicense to an Affiliate only while such entity
is and remains an Affiliate;

 

(ii)such sublicense automatically and immediately terminates upon such entity no
longer being an Affiliate of Novvi LLC;

 

(iii)each such sublicense to an Affiliate shall be in writing and contain terms
that are consistent in all material respects with this License Agreement
including confidentiality terms regarding non-disclosure and non-use of Amyris
Confidential Information and provisions governing intellectual property rights
and obligations;

 

Page 7 of 37

CONFIDENTIAL

(iv)Novvi LLC shall only grant such a sublicense subject to terms that prohibit
the Affiliate from using the sublicensed Amyris Base Technology for any purpose
other than to Exploit a Base Oil, Additive, or Lubricant derived from BioFene
solely for the Lubricants Market;

 

(v)Novvi LLC shall reasonably monitor such sublicensed Affiliate to ensure it is
not violating the prohibition in clause (iv), its confidentiality obligations,
or its intellectual property obligations in a manner consistent with the
procedures Novvi LLC uses to monitor its own licensees and sublicensees to
ensure proper use of Novvi LLC’s intellectual property, but no less than
commercially reasonable efforts;

 

(vi)Novvi LLC shall retain the right to terminate any such sublicense in the
event the applicable sublicensed Affiliate violates the prohibition in clause
(iv), its confidentiality obligations, or its intellectual property obligations;
and

 

(vii)Novvi LLC shall immediately terminate any such sublicense in the event the
applicable sublicensed Affiliate violates the prohibition in clause (iv), its
confidentiality obligations, or its intellectual property obligations and fails
to cure such breach within a reasonable period, which, in no event, shall exceed
thirty (30) days after written notice.

 

(c) Limited Sublicense to Third Party Manufacturing and R&D Subcontractors.
Novvi LLC may not sublicense any of its rights under the licenses granted in
Subsections (a)(i) or (iii) to Third Parties, except to a Third Party that is
(x) manufacturing for Novvi LLC or an Affiliate of Novvi LLC, in a subcontractor
role, a Base Oil, Additive, and/or Lubricant derived from BioFene for the
Lubricants Market or (y) performing research and development for Novvi LLC or an
Affiliate of Novvi LLC, in a subcontractor role, on a Base Oil, Additive, and/or
Lubricant derived from BioFene for the Lubricants Market; provided, that,:

 

(i)Novvi LLC shall grant such Third Party manufacturing subcontractor a
sublicense only to make, solely for Novvi LLC or its Affiliates, either a Base
Oil, Additive, and/or Lubricant, as the case may be, derived from BioFene solely
for the Lubricants Market; shall grant such Third Party R&D subcontractor a
sublicense only to perform research and development, solely for Novvi LLC or its
Affiliates, of Base Oils, Additives, and/or Lubricants, as the case may be,
derived from BioFene solely for the Lubricants Market; and, in each case, shall
prohibit such sublicensed Third Party subcontractors from using the sublicensed
Amyris Base Technology for any other purpose;

 

(ii)each such sublicense agreement shall be in writing and contain terms that
are consistent in all material respects with this License Agreement including
confidentiality terms regarding non-disclosure and non-use of Amyris
Confidential Information and provisions governing intellectual property rights
and obligations;

 

(iii)Novvi LLC shall reasonably monitor such sublicensed Third Party
subcontractors to ensure they are not violating the prohibitions in clause (i),
their confidentiality obligations, or their intellectual property obligations in
a manner consistent with the procedures Novvi LLC uses to monitor its own
licensees and sublicensees to ensure proper use of Novvi LLC’s intellectual
property, but no less than commercially reasonable efforts;

 

(iv)Novvi LLC shall retain the right to terminate any such sublicense in the
event the applicable sublicensed Third Party subcontractor violates the
prohibitions in clause (i),

 

Page 8 of 37

CONFIDENTIAL

its confidentiality obligations, or its intellectual property obligations; and

 

(v)Novvi LLC shall immediately terminate any such sublicense in the event the
applicable sublicensed Third Party subcontractor violates the prohibitions in
clause (i), its confidentiality obligations, or its intellectual property
obligations and fails to cure such breach within a reasonable period, which, in
no event, shall exceed thirty (30) days after written notice.

 

(d) No Right to Manufacture BioFene. For clarity, under the licenses granted in
Subsection (a) above, Novvi LLC has no right to make or have made BioFene under
any Amyris intellectual property. The rights of Novvi LLC to make or have made
BioFene are set forth in Section 2.3.

 

2.2 License to Amyris under Novvi LLC BioFene Transformation Technology.

 

(a) License. Subject to the terms and conditions in this License Agreement,
Novvi LLC hereby grants Amyris an exclusive, worldwide, royalty-free, fully
paid-up, sublicensable, and non-assignable license under Novvi LLC BioFene
Transformation Technology for any use other than to Exploit Base Oils,
Additives, or Lubricants derived from BioFene for the Lubricants Market.

 

(b) Sublicense Rights. Amyris may sublicense any of its rights under the license
granted in Subsection (a) through multiple tiers of sublicensees; provided,
that,:

 

(i)Amyris shall only grant such sublicenses subject to terms that prohibit all
such sublicensees, including direct sublicensees, any sublicensees of such
sublicensees, or any other sublicensee pursuant to one of the multiple tiers of
such sublicenses, from using the sublicensed Novvi LLC BioFene Transformation
Technology to Exploit any Base Oil, Additive, or Lubricant derived from BioFene
for the Lubricants Market;

 

(ii)each such sublicense agreement shall be in writing and contain terms that
are consistent in all material respects with this License Agreement including
confidentiality terms regarding non-disclosure and non-use of Novvi LLC’s
Confidential Information and provisions governing intellectual property rights
and obligations;

 

(iii)Amyris shall reasonably monitor such sublicensees to ensure they are not
violating the prohibition in clause (i), their confidentiality obligations, or
their intellectual property obligations in a manner consistent with the
procedures Amyris uses to monitor its own licensees and sub-licensees to ensure
proper use of Amyris’s intellectual property, but no less than commercially
reasonable efforts;

 

(iv)Amyris shall retain the right to terminate any such sublicense in the event
the applicable sublicensee violates the prohibition in clause (i), its
confidentiality obligations, or its intellectual property obligations; and

 

(v)Amyris shall immediately terminate any such sublicense in the event the
applicable sublicensee violates the prohibition in clause (i), its
confidentiality obligations, or its intellectual property obligations and fails
to cure such breach within a reasonable period, which, in no event, shall exceed
thirty (30) days after written notice.

 

2.3 License to Novvi LLC to Manufacture BioFene under Amyris BioFene
Manufacturing Technology.

Page 9 of 37

CONFIDENTIAL

(a) Non-Exclusive License to Manufacture BioFene. Amyris grants, subject to the
conditions described below, Novvi LLC a non-exclusive, non-assignable,
royalty-free, and non-sublicensable (except as necessary to exercise its “have
made” rights using Third Party subcontractor manufacturers or Affiliates)
license under Amyris BioFene Manufacturing Technology to make and have made
BioFene solely to produce Novvi LLC’s (and, if applicable, Novvi LLC’s
Affiliates’) Base Oils, Additives, and Lubricants derived from BioFene for the
Lubricants Market.

 

(b) Conversion to a Royalty-Bearing License. Should Amyris no longer own any
membership units or other equity interest in Novvi LLC (the “License Conversion
Event”), the royalty-free license granted to Novvi LLC under subsection (a)
above automatically becomes royalty-bearing, and within thirty (30) days after
the License Conversion Event, the Parties will agree in writing upon a
commercially-reasonable royalty rate and terms for such license. In the event
the Parties do not agree within such time period, the Parties will promptly
engage in an accelerated “baseball arbitration” process to determine a
commercially-reasonable royalty rate and terms for the license.

 

(c) Escrowed Materials. By September 1, 2016, Amyris shall deposit with SciSafe
Inc. (the “Escrow Agent”), pursuant to the Escrow Agreement, (1) the Production
Strain presently used by Amyris to commercially produce BioFene and (2) the
process, including the applicable standard operating procedures (“SOPs”),
presently used by Amyris to commercially produce BioFene with such escrowed
Production Strain (collectively (1) and (2), as annually updated per the next
paragraph, the “Escrowed Materials”).

 

Amyris shall, on or about every June 30, update the Escrowed Materials by
replacing the escrowed Production Strain with the Production Strain then being
used by Amyris to commercially produce BioFene and replacing the escrowed
BioFene production process information with the process, including the
applicable SOPs, then used by Amyris to commercially produce BioFene with the
newly escrowed Production Strain. Amyris’s obligations to update the Escrowed
Materials shall terminate upon the earlier of (i) the date the Escrowed
Materials are released to Novvi LLC per the procedures in the Escrow Agreement
and (ii) thirty (30) days after the date on which Amyris concludes its BioFene
strain development program.

 

(d) Release of Escrowed Materials to Novvi LLC. Upon release of the Escrowed
Materials to Novvi LLC per the procedures in the Escrow Agreement, Novvi LLC may
use the Escrowed Materials only to exercise its license under Subsection (a)
above and only at a manufacturing location (whether such location is owned by
Novvi LLC, a Novvi LLC Affiliate, or a Third Party) approved in advance by
Amyris in writing, which approval will not be unreasonably withheld. Immediately
upon expiration or earlier termination of its license in Subsection (a), Novvi
LLC will cease its and any Affiliate’s or Third Party’s use of, and will
properly destroy, all of the Production Strain, the other Escrowed Materials,
and any other intellectual property of Amyris in Novvi LLC’s, a Novvi LLC’s
Affiliate’s or a Third Party’s possession and certify such destruction in
writing to Amyris. Novvi LLC may not, and shall not allow any other person or
entity to, reverse engineer, engineer, or otherwise genetically modify the
Production Strain or to genetically modify engineer any other strain from the
Production Strain and, except as expressly permitted in this Section 2.3, may
not to distribute, disclose or transfer the Production Strain, the other
Escrowed Materials, or any other intellectual property of Amyris to any other
person or entity. Despite a release to Novvi LLC, the Escrowed Materials remain
the exclusive property and Confidential Information of Amyris, and such release
does not grant any ownership rights or, except as specifically set forth herein,
any other rights of use, express or implied, in the Escrowed Materials to Novvi
LLC or any other person or entity.

 

(e) Manufacturing through an Affiliate or Third Party. To the extent Novvi LLC,
in the exercise of its “have made” rights under Subsection (a), desires to
engage an Affiliate or Third Party to

Page 10 of 37

CONFIDENTIAL

produce BioFene for it, such Affiliate or Third Party must execute a binding
written contract with Novvi LLC, subject to Amyris’s prior written approval,
containing at least the following provisions before Novvi LLC provides any of
the released Escrowed Materials (including the applicable Production Strain) to
such Affiliate or Third Party:

 

(i)a covenant by the Affiliate or Third Party to not use the Escrowed Materials
except to make BioFene solely for Novvi LLC per Novvi LLC’s license under
Section 2.3(a);

 

(ii)a covenant by the Affiliate or Third Party to not reverse engineer the
Production Strain, to not to engineer or genetically modify the Production
Strain, and to not distribute, disclose or transfer the Production Strain, the
other Escrowed Materials, or any related intellectual property of Amyris to any
other person or entity;

 

(iii)a covenant by the Affiliate or Third Party to hold in strict confidence,
and to take all reasonable precautions to protect, the Escrowed Materials
(including the Production Strain) and any other Confidential Information of
Amyris that it obtains and to not divulge any of such information or any
information derived therefrom to any person, except an employee who has a need
to know for the Affiliate or Third Party to produce BioFene for Novvi LLC;

 

(iv)a covenant by the Affiliate or Third Party that its manufacture and supply
of BioFene on behalf of Novvi LLC will, at all times, be conducted in accordance
with applicable laws, rules and regulations;

 

(v)automatic termination of the Affiliate’s or Third Party’s contract with Novvi
LLC and of its use and possession of the Production Strain, the other Escrowed
Materials, or any other intellectual property of Amyris upon the Affiliate’s or
Third Party’s breach of such contract;

 

(vi)a covenant by the Affiliate or Third Party that, immediately following
termination of the Affiliate’s or Third Party’s contract with Novvi LLC, it will
properly destroy all of the Production Strain, the other Escrowed Materials, or
any other intellectual property of Amyris in the Affiliate’s or Third Party’s
possession and certify such destruction in writing to Amyris;

 

(vii)Amyris has the right, at least once per calendar quarter, upon reasonable
prior notice and during normal business hours, to inspect such Affiliate’s or
Third Party’s facilities at which BioFene is being manufactured;

 

(viii)Amyris has the right, upon reasonable prior notice and during normal
business hours, to have a representative present from time-to-time during the
Affiliate’s or Third Party’s manufacture of BioFene;

 

(ix)Amyris is expressly named in the contract as a third party beneficiary with
the right to enforce such contract against the Affiliate or Third Party;

 

(x)Amyris, as third party beneficiary, is entitled to injunctive or other
equitable remedies, in addition to all other available remedies, against the
Affiliate’s or Third Party’s breach or threatened breach of contract with regard
to the Production Strain, the other Escrowed Materials, or any other
intellectual property of Amyris without the necessity of showing irreparable
harm, balancing of harms, consideration of the public interest or

Page 11 of 37

CONFIDENTIAL

inadequacy of monetary damages as a remedy and without posting any bond or other
security as a condition for obtaining any such relief and the Affiliate or Third
Party irrevocably and unconditionally waives any such requirements;

 

(xi)agreement by the Affiliate or Third Party to fully defend, indemnify, and
hold harmless Amyris for the Affiliate’s or Third Party’s actions, inactions or
breaches under such contract; and

 

(xii)agreement by the Affiliate or Third Party that to obtain and maintain
insurance coverage with a reputable carrier at coverage amounts commercially
reasonable for its activities and commitments under such contract.

 

Amyris and Novvi LLC agree that Amyris has the primary right, but not
obligation, to pursue actions against the Affiliate or Third Party to protect
the Production Strain, other Escrowed Materials, and other intellectual property
of Amyris.

 

(f) Tech Transfer. Upon release of the Escrowed Materials to Novvi LLC per the
procedures in the Escrow Agreement, Amyris agrees to provide a one-time,
site-specific, and reasonable amount (but no more than one hundred (100) hours)
of technical assistance to Novvi LLC to enable Novvi LLC to implement the
Escrowed Materials consistent with the license in subsection (a). However, due
to the potential variances in manufacturing facilities, equipment, capabilities,
personnel, experience, locations, infrastructure, and/or operations, there is no
guarantee of successful implementation or performance of the Escrowed Materials
at any facility, even after the one-time technical assistance.

 

(g) Disputes. Any dispute between the Parties regarding the deposit or release
of the Escrowed Materials shall be resolved as provided in Section 8.2.

 

2.4 No Implied or Additional Rights or Licenses. Except as specified in this
License Agreement, Amyris grants no rights to Novvi LLC to use any of Amyris’s
Confidential Information or intellectual property. Except as specified in this
License Agreement, Novvi LLC grants no rights or licenses to Amyris to use any
of Novvi LLC’s Confidential Information or intellectual property.

 

2.5 Novvi LLC Efforts in Brazil. Novvi LLC agrees it will exert commercially
reasonable efforts to use the licensed technology in order to try to maintain
the validity of the Patents in the Amyris Base Technology and, if licensed to
Novvi LLC, in the Amyris BioFene Manufacturing Technology and any Alternative
Technology, in each case in the territory of Brazil.

 

2.6 Effect of Bankruptcy on the Licenses. All rights and licenses granted under
this Article 2 by Amyris or Novvi LLC are, and shall otherwise be deemed to be,
for purposes of Section 365(n) of the U.S. Bankruptcy Code (the “Code”),
licenses of rights to “intellectual property” as defined under Section 101 of
the Code. The Parties agree that, in the event of a Party’s Insolvency Event,
the other Party in its capacity as a licensee under this Article 2 will, to the
extent that its license is still in effect at the time of such Insolvency Event,
retain and may fully exercise all of its rights and elections under the Code (or
any same or similar provision in any jurisdiction other than the United States)
with regard to such license and rights, subject to payments due the licensor
Party (if any) as a result of the exercise of such rights and subject to the
terms and conditions of such license and rights set forth in this License
Agreement.

 

The Parties further agree that, in any Insolvency Event involving a Party, that
the other Party will be entitled to a complete duplicate of (or complete access
to, as appropriate) any such intellectual property

Page 12 of 37

CONFIDENTIAL

licensed to such licensee Party under its continuing license and all tangible
embodiments of such intellectual property, and same, if not already in its
possession, will be promptly delivered to the licensee Party (i) upon any such
commencement of a bankruptcy proceeding upon such licensee Party’s written
request or (ii) if not promptly delivered under (i) above, following any
rejection of this License Agreement by or on behalf of such Party (e.g. by a
bankruptcy trustee), upon written request for such transfer by the licensee
Party. For the avoidance of doubt, nothing in this clause may be construed as
forcing a Party to act in breach of any mandatory bankruptcy laws and
regulations applicable in its jurisdiction.

 

 

ARTICLE 3

 

RIGHT OF FIRST OFFER REGARDING ALTERNATIVE TECHNOLOGY

 

3.1 Right of First Offer to Amyris’s Alternative Technology. Notwithstanding the
exclusivity provisions in Section 13.01 of the Second Amended and Restated
Operating Agreement, if while Novvi LLC’s licenses under Section 2.1 are in
effect, Amyris (i) develops, acquires, or in-licenses an Alternative Technology
and (ii) wishes to exclusively license or sell to a Third Party the use or
ownership of such Alternative Technology for purposes of developing, making
(having made), offering for sale, selling, or importing Base Oils, Additives, or
Lubricants for the Lubricants Market, then, prior to engaging in a discussion
with any Third Party or soliciting an offer from any Third Party in this
respect, Amyris shall first offer Novvi LLC the right to exclusively license or
acquire (subject to the Exclusivity Exceptions) use or ownership of such
Alternative Technology for the development, making (having made), offering for
sale, sale, and importation of Base Oils, Additives, and Lubricants solely in
the Lubricants Market (“ROFO”); provided such ROFO does not violate the terms of
any arrangement with any Third Party from whom Amyris acquired or licensed such
Alternative Technology, if applicable.

 

For the avoidance of doubt, the foregoing ROFO obligation shall not apply to an
Alternative Technology developed by Amyris in connection with activities that
fall within an Exclusivity Exception.

 

3.2 ROFO Notice. Amyris shall promptly notify Novvi LLC in writing when it has
an Alternative Technology that is subject to the ROFO (a “ROFO Notice”). The
ROFO Notice shall include a reasonable description of the applicable Alternative
Technology and the fundamental license and/or sale terms and conditions proposed
by Amyris.

 

3.3 Exercise of the ROFO.

 

(a) Due Diligence Period. Novvi LLC shall have sixty (60) days from receipt of a
ROFO Notice to (i) conduct an assessment of the applicable Alternative
Technology (and, for such purpose, Amyris hereby undertakes to provide to Novvi
LLC all information it believes in good faith is necessary for Novvi LLC’s full
and complete assessment) and (ii) deliver to Amyris a written notice expressing
its intention to exercise its ROFO (an “Exercise Notice”).

 

(b) Negotiation Period. In the event it delivers an Exercise Notice per
Subsection (a) above, Novvi LLC shall be obligated, within sixty (60) days from
Amyris’s receipt of the Exercise Notice, to enter into a definitive agreement
with Amyris (separate from this License Agreement) regarding either an exclusive
license to, or acquisition of, (subject to the Exclusivity Exceptions) the use
or ownership of such Alternative Technology for the development, making (having
made), offering for sale, sale, and importation of Base Oils, Additives, and
Lubricants solely in the Lubricants Market and on terms and conditions
consistent with those referred to in the ROFO Notice. In addition, any license
granted by

Page 13 of 37

CONFIDENTIAL

Amyris to Novvi LLC with regard to Alternative Technology shall be terminable
upon the expiration or earlier termination of Novvi LLC’s licenses under Section
2.1.

 

(c) Negotiate with Third Parties. If Novvi LLC does not deliver an Exercise
Notice in compliance with Subsection (a) above or is not successful in executing
a definitive agreement with Amyris within the sixty (60) days in Subsection (b)
above, then Amyris shall be free to solicit and negotiate with any Third Party
the exclusive license or sale of such Alternative Technology, provided that (i)
the economic terms offered by such Third Party shall be no less favorable to
Amyris than those offered by Novvi LLC under the ROFO Notice; (ii) the
fundamental business terms, including the structure of the relevant transaction
(e.g., sale, license, formation of a joint venture and contribution of the
Alternative Technology), are substantially the same as those offered to Novvi
LLC under the ROFO Notice; and (iii) Amyris and the Third Party have entered
into a definitive agreement within one hundred and twenty (120) days after the
end of the sixty (60) day period in Subsections (a) or (b) above, whichever is
applicable.

 

3.4 Repetition of ROFO. If Amyris and the Third Party have not entered into a
definitive agreement in compliance with Section 3.3(c) above, then Amyris must
again comply with the provisions of the ROFO before exclusively licensing or
selling to a Third Party the use or ownership of such Alternative Technology for
purposes of Base Oils, Additives, or Lubricants in the Lubricants Market.

 

3.5 Alternative Technology Production Strain Restrictions. If an Alternative
Technology to be exclusively licensed to Novvi LLC by Amyris under this Article
3 includes rights for Novvi LLC to manufacture or have manufactured such
Alternative Technology with a Production Strain, the Parties hereby agree that
such manufacturing license granted to Novvi LLC shall be conditioned on, among
other things, compliance with provisions equivalent to those for BioFene in
Section 2.3 above.

 

3.6 Termination of Article 3. Upon the expiration or earlier termination of
Novvi LLC’s licenses under Section 2.1, all rights and obligations of the
Parties under this Article 3 automatically terminate, and this Article 3 will be
of no further effect.

 

 

ARTICLE 4

 

SALE OF BY-PRODUCTS

 

4.1 No Sale of By-Products as Diesel Fuel in the European Union. Novvi LLC
agrees that it shall not, at any time, offer for sale or sell any By-Products,
including, but not limited to, any farnesane or diesel-related By-Products
(“Diesel By-Products”), for use in or as diesel fuel in any of the European
Union.

 

4.2 No Sale of Jet Fuel By-Products except to Amyris; Amyris’s Obligation to
Purchase.

 

(a)                Novvi LLC agrees that it will not offer for sale or sell any
Jet Fuel By-Products to any person or entity except to Amyris as set forth in
this Section 4.2, and Amyris agrees that it will purchase all such Jet Fuel
By-Products. As used in this Section, “Jet Fuel By-Product” means a By-Product
(i) whose concentration of farnesane, partially hydrogenated farnesene or
farnesene, by volume, is at least [*] or greater; and (ii) that when blended
with petroleum-derived jet fuel, meets the ASTM D1655 and D7566 specifications
(or successors thereto) for use as a jet fuel.

 

(b)               The purchase price payable by Amyris to Novvi LLC for each
liter of any Jet Fuel By-Product will be equal to the price per liter that
Amyris sells farnesene to Novvi LLC, in case such

 

[*] Certain portions denoted with an asterisk have been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions.

Page 14 of 37

CONFIDENTIAL

price is higher than US$ [*] per liter. If the per liter of farnesene price
Amyris charges to Novvi LLC is below US$ [*] per liter, Amyris will purchase
such Jet Fuel By-Product at the NYMEX ULSD diesel one-month forward price.

 

(c)                In connection with the sale of any By-Products by Novvi LLC
to a third party, Novvi LLC shall require any such purchaser to agree in writing
that (i) such By-Products may not be used in or as diesel fuel in the European
Union or in or as jet fuels anywhere, and (ii) if any such By-Products are
incorporated into any diesel fuel outside the European Union, that such diesel
fuels may not be imported into any of the European Union.

 

(d)               Other than as set forth in this Section, Amyris has no
obligation or rights to purchase any By-Products from Novvi LLC.

 

4.3 No Other Limits on Novvi LLC. Other than as set forth in this Article 4,
Novvi LLC may, pursuant to its license in Section 2.1(a)(ii), freely offer for
sale, sell, and import its By-Products.

 

ARTICLE 5

 

INTELLECTUAL PROPERTY

 

5.1 Inventorship. Inventorship of all inventions and discoveries conceived,
reduced to practice, discovered or made pursuant to this License Agreement,
whether or not patentable, shall be determined in accordance with U.S. patent
laws. Other than as set forth below, as among the Parties, ownership of all
inventions and discoveries conceived, reduced to practice, discovered or made or
created during the Term of this License Agreement shall be determined consistent
with inventorship.

 

5.2 Amyris’s Ownership. Amyris’s intellectual property ownership rights are as
follows:

 

(a)                Amyris Base Technology, Amyris BioFene Manufacturing
Technology, Amyris Inventions, and Amyris Alternative Technology. As between the
Parties, all rights, title, and interest in and to Amyris Base Technology,
Amyris BioFene Manufacturing Technology, Amyris Inventions, and Amyris’s
Alternative Technology are exclusively owned solely by Amyris. Novvi LLC and its
Affiliates, sublicensees, contractors, agents, and employees shall have no
right, license or permission to practice Amyris Base Technology, Amyris BioFene
Manufacturing Technology, or Amyris Inventions, or Amyris’s Alternative
Technology except to the extent the licenses described in Sections 2.1 and 2.3
or Article 3 are in place between the Parties.

 

(b)               Joint BioFene Manufacturing Improvements and Novvi LLC BioFene
Manufacturing Improvements. All rights, title, and interest in and to Joint
BioFene Manufacturing Improvements and Novvi LLC BioFene Manufacturing
Improvements are exclusively owned solely by Amyris. Novvi LLC will promptly
disclose Joint BioFene Manufacturing Improvements and Novvi LLC BioFene
Manufacturing Improvements, if any, in writing to Amyris and, without further
consideration, hereby assigns to Amyris any and all rights, title and interests
of Novvi LLC (and, as applicable, its Affiliates, sublicensees, contractors,
agents, and employees) in and to all Joint BioFene Manufacturing Improvements
and Novvi LLC BioFene Manufacturing Improvements.

 

Upon Amyris’s reasonable request and at Amyris’s expense, Novvi LLC will
promptly perform (or cause, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees to promptly perform) any and all acts
necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other
documentation as may be reasonably required, to perfect the delivery,
assignment, and conveyance to Amyris, its successors, assigns, and nominees, of

 

[*] Certain portions denoted with an asterisk have been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment
has been requested with respect to the omitted portions.

Page 15 of 37

CONFIDENTIAL

the entire right, title, and interest in and to all Joint BioFene Manufacturing
Improvements and Novvi LLC BioFene Manufacturing Improvements.

 

For purposes of this License Agreement, Joint BioFene Manufacturing Improvements
and Novvi LLC BioFene Manufacturing Improvements will be considered Amyris
BioFene Manufacturing Technology, and Novvi LLC and its Affiliates,
sublicensees, contractors, agents, and employees shall have no right, license or
permission to practice Joint BioFene Manufacturing Improvements or Novvi LLC
BioFene Manufacturing Improvements except to the extent the license described in
Section 2.3 is in place between the Parties.

 

(c)                Novvi LLC Breach Inventions. All rights, title, and interest
in and to Novvi LLC Breach Inventions are also exclusively owned solely by
Amyris. Novvi LLC will promptly disclose Novvi LLC Breach Inventions, if any, in
writing to Amyris and, without further consideration, hereby assigns to Amyris
any and all rights, title and interests of Novvi LLC (and, as applicable, its
Affiliates, sublicensees, contractors, agents, and employees) in and to Novvi
LLC Breach Inventions.

 

Upon Amyris’s reasonable request and at Amyris’s expense, Novvi LLC will
promptly perform (or cause, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees to promptly perform) any and all acts
necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other
documentation as may be reasonably required, to perfect the delivery,
assignment, and conveyance to Amyris, its successors, assigns, and nominees, of
the entire right, title, and interest in and to all Novvi LLC Breach Inventions.

 

For purposes of this License Agreement, Novvi LLC Breach Inventions will be
considered Amyris Inventions, and Novvi LLC and its Affiliates, sublicensees,
contractors, agents, and employees shall have no right, license or permission to
practice Novvi LLC Breach Inventions.

 

5.3 Novvi LLC’s Ownership. Novvi LLC’s intellectual property ownership rights
are as follows:

 

(a) Novvi LLC BioFene Transformation Technology and Novvi LLC Inventions. As
between the Parties, all rights, title, and interest in and to Novvi LLC BioFene
Transformation Technology and Novvi LLC Inventions are exclusively owned solely
by Novvi LLC. Amyris and its Affiliates, sublicensees, contractors, agents, and
employees shall have no right, license or permission to practice Novvi LLC
BioFene Transformation Technology or Novvi LLC Inventions except to the extent
the license described in Section 2.2 is in place between the Parties.

 

(b) Amyris Breach Inventions. All rights, title, and interest in and to Amyris
Breach Inventions are also exclusively owned solely by Novvi LLC. Amyris will
promptly disclose Amyris Breach Inventions, if any, in writing to Novvi LLC and,
without further consideration, hereby assigns to Novvi LLC any and all rights,
title and interests of Amyris (and, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees) in and to Amyris Breach Inventions.

 

Upon Novvi LLC’s reasonable request and at Novvi LLC’s expense, Amyris will
promptly perform (or cause, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees to promptly perform) any and all acts
necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other
documentation as may be reasonably required, to perfect the delivery,
assignment, and conveyance to Amyris, its successors, assigns, and nominees, of
the entire right, title, and interest in and to all Amyris Breach Inventions.

 

For purposes of this License Agreement, Amyris Breach Inventions will be
considered Novvi Inventions,

Page 16 of 37

CONFIDENTIAL

and Amyris and its Affiliates, sublicensees, contractors, agents, and employees
shall have no right, license or permission to practice Amyris Breach Inventions.

 

5.4 Joint Inventions. Joint Inventions will be jointly owned by Amyris and Novvi
LLC, and the Parties will have co-exclusive rights to use and practice Joint
Inventions (i.e., neither Party can individually grant another person or entity
any exclusive rights) and without accounting.

 

5.5 Semi-Annual Updates to Amyris regarding Novvi LLC BioFene Transformation
Technology. Every January 15 and July 15 while Amyris’s license under Section
2.2 is in effect, Novvi LLC will provide Amyris with a written update on Novvi
LLC BioFene Transformation Technology. Such semi-annual updates will include a
list of any Patents in the Novvi LLC BioFene Transformation Technology
identified by their respective title, inventors, serial numbers, filing date,
and status. Novvi LLC also agrees to copy Amyris on any official correspondence
between Novvi LLC (or Novvi LLC’s counsel) and any patent office regarding
Patents in Novvi LLC BioFene Transformation Technology.

 

5.6 Semi-Annual Updates to Novvi LLC regarding Amyris Base Technology. Every
January 15 and July 15 while Novvi LLC’s license under Section 2.1 is in effect,
Amyris will provide Novvi LLC with a written update on Amyris Base Technology.
Such semi-annual updates will include a list of any Patents in the Amyris Base
Technology identified by their respective title, inventors, serial numbers,
filing date, and status. Amyris also agrees to copy Novvi LLC on any official
correspondence between Amyris (or Amyris’ counsel) and any patent office
regarding Patents in Amyris Base Technology.

 

5.7 Semi-Annual Updates to Novvi LLC regarding Amyris BioFene Manufacturing
Technology. Following the technical transfer from Amyris to Novvi LLC described
in Section 2.3, every January 15 and July 15 while Novvi LLC’s license under
Section 2.3 remains in effect, Amyris will provide Novvi LLC with a written
update on Amyris BioFene Manufacturing Technology. Such semi-annual updates will
include a list of any Patents in the Amyris BioFene Manufacturing Technology
identified by their respective title, inventors, serial numbers, filing date,
and status. Amyris also agrees to copy Novvi LLC on any official correspondence
between Amyris (or Amyris’ counsel) and any patent office regarding Patents in
Amyris BioFene Manufacturing Technology.

 

5.8 Patent Strategy and Prosecution.

 

(a) Amyris’s Rights. As between the Parties, Amyris shall have the sole right
and discretion to: (i) determine the process for protecting any Amyris
Inventions (as well as any Amyris Base Technology and any Amyris BioFene
Manufacturing Technology) worldwide, including whether or not to obtain Patent
protection and in what countries and (ii) at its own expense, but without
obligation, prepare, file, prosecute, maintain, and defend throughout the world
any and all Patents claiming or relating to the Amyris Inventions, Amyris Base
Technology and Amyris BioFene Manufacturing Technology or, at any time, abandon
or discontinue such activities.

 

Upon Amyris’s reasonable request and at Amyris’s expense, Novvi LLC will
promptly perform (or cause, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees to promptly perform) any and all acts
necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other
documentation as may be reasonably required, to allow Amyris to apply for,
register, obtain, maintain, defend, and enforce any Patent claiming or relating
to any Joint BioFene Manufacturing Improvements, Novvi LLC BioFene Manufacturing
Improvements, or Novvi LLC Breach Inventions and/or its rights therein.

 

(b) Novvi LLC’s Rights. As between the Parties, Novvi LLC shall have the sole
right and

 

Page 17 of 37

CONFIDENTIAL

discretion to (i) determine the process for protecting any Novvi LLC Inventions
(as well as any Novvi LLC BioFene Transformation Technology) worldwide,
including whether or not to obtain Patent protection and in what countries and
(ii) at its own expense, but without obligation, prepare, file, prosecute,
maintain, and defend throughout the world any and all Patents claiming or
relating to the Novvi LLC Inventions and Novvi LLC BioFene Transformation
Technology or, at any time, abandon or discontinue such activities.

 

Upon Novvi LLC’s reasonable request and at Novvi LLC’s expense, Amyris will
promptly perform (or cause, as applicable, its Affiliates, sublicensees,
contractors, agents, and employees to promptly perform) any and all acts
necessary, including the execution and delivery of any and all affidavits,
declarations, oaths, exhibits, assignments, powers of attorney, or other
documentation as may be reasonably required, to allow Novvi LLC to apply for,
register, obtain, maintain, defend, and enforce any Patent claiming or relating
to any Amyris Breach Invention and/or its rights therein.

 

(c) Joint Inventions Rights. For each Joint Invention, the Parties will mutually
select which Party shall have the sole right and discretion to (i) determine the
process for protecting such Joint Invention worldwide, including whether or not
to obtain Patent protection and in what countries and (ii) at its own expense,
but without obligation, prepare, file, prosecute, maintain, and defend
throughout the world any and all Patents claiming or relating to such Joint
Invention or, at any time, abandon or discontinue such activities.

 

5.9 Infringement by Third Parties.

 

(a) Amyris Base Technology and Amyris BioFene Manufacturing Technology. In the
event either Party becomes aware of any Third Party activity that infringes or
misappropriates (or is likely to infringe or misappropriate) Amyris Base
Technology or Amyris BioFene Manufacturing Technology, that Party will notify
the other Party promptly in writing of the actual or threatened infringement or
misappropriation. Whether or not to take action against such infringement or
misappropriation will be the sole right, and at the sole discretion, of Amyris
or its designated representative (“Amyris Designate”). However, at Amyris’s
expense, Novvi LLC will cooperate to the extent reasonably required by Amyris or
the Amyris Designate to stop such infringement or misappropriation, and, if so
requested by Amyris, will join with Amyris or the Amyris Designate as a party to
any action brought by Amyris or the Amyris Designate for such purpose. Amyris or
the Amyris Designate will have full control over any action taken, including,
without limitation, the right to select counsel, to settle on any terms it deems
advisable in its discretion, to appeal any adverse decision rendered in any
court, to discontinue any action taken by it, and otherwise to make any decision
in respect thereto as it in its discretion deems advisable.

 

(b) Novvi LLC BioFene Transformation Technology. In the event either Party
becomes aware of any Third Party activity that infringes or misappropriates (or
is likely to infringe or misappropriate) Novvi LLC BioFene Transformation
Technology, that Party will notify the other Party promptly in writing of the
actual or threatened infringement or misappropriation. Whether or not to take
action against such infringement or misappropriation will be the sole right, and
at the sole discretion, of Novvi LLC or its designated representative (“Novvi
LLC Designate”). However, Amyris will cooperate to the extent reasonably
required by Novvi LLC or the Novvi LLC Designate to stop such infringement or
misappropriation, and, if so requested by Novvi LLC, will join with Novvi LLC or
the Novvi LLC Designate as a party to any action brought by Novvi LLC or the
Novvi LLC Designate for such purpose. Novvi LLC or the Novvi LLC Designate will
have full control over any action taken, including, without limitation, the
right to select counsel, to settle on any terms it deems advisable in its
discretion, to appeal any adverse decision rendered in any court, to discontinue
any action taken by it, and otherwise to make any decision in respect thereto as
it in its discretion deems advisable.

Page 18 of 37

CONFIDENTIAL

5.10 Confidentiality Obligations.

 

(a) Confidential Information. As used herein, “Confidential Information” means
any and all information provided by or on behalf of a Party (“Disclosing Party”)
to the other Party (“Receiving Party”) or to its Representatives between the
Effective Date and the termination of this License Agreement, regardless of the
form or medium of communication, that relates to the Disclosing Party’s
intellectual property licensed or created under this License Agreement or its
activities under this License Agreement, in each case which information is
either proprietary to the Disclosing Party or is otherwise not available to the
general public. The Parties agree to treat this License Agreement as the
Confidential Information of the other Party. As used herein, “Representative”
means the officers, directors, members, shareholders, employees, attorneys,
accountants, advisors, consultants, auditors, agents, contractors, and
sublicensees of the applicable Party and of its Affiliates.

 

(b) Obligations. Except with the prior written consent of the Disclosing Party
or as specifically authorized in this License Agreement, each Receiving Party
shall, and shall cause its Representatives (to the extent such persons receive
any Confidential Information) to,:

 

(i)maintain in confidence any and all Confidential Information;

 

(ii)take reasonable precautions to protect Confidential Information;

 

(iii)not disclose Confidential Information to any person or entity; and

 

(iv)not make any use of such Confidential Information except for the purposes
specifically authorized herein.

 

(c) Permitted Disclosures. A Receiving Party may disclose Confidential
Information, without the Disclosing Party’s written consent, to those of its
Representatives who (i) need to know such Confidential Information for the
purpose of assisting such Receiving Party fulfill its obligations or exercise
its rights under this License Agreement and (ii) are bound by written
obligations of confidentiality and non-use substantially similar to those
herein. A Receiving Party or its Affiliates may also disclose the terms of this
License Agreement to actual or prospective investors, underwriters, or acquirers
who need to know such Confidential Information to evaluate the Receiving Party’s
(or its Affiliates’) business and who are bound by written obligations of
confidentiality and non-use substantially similar to those herein.

 

(d) Legally Required Disclosures. In addition, a Receiving Party may disclose
Confidential Information (including the terms of this License Agreement),
without the Disclosing Party’s written consent, to the extent such disclosure is
required, on advice of counsel, by Applicable Law (including pursuant to any
listing agreement with, or the rules or regulations of, any national securities
exchange on which any securities of such Receiving Party or any Affiliate
thereof are listed or traded); provided, that the Receiving Party making such
disclosure, or whose Affiliates are making such disclosure, shall notify the
other Party as promptly as practicable (and if possible and legally allowed,
prior to making such disclosure) and shall minimize such disclosure as much as
possible and reasonably seek confidential treatment of such Confidential
Information to the extent available.

 

(e) Exceptions to Confidential Information. The provisions of Subsection (b)
above shall not apply to, and Confidential Information shall not include, any
information of a Disclosing Party that:

 

(i)is or has become generally available to the public other than as a result of
a disclosure by a Receiving Party or any of its Representatives in breach of
this Section 5.10;

Page 19 of 37

CONFIDENTIAL

(ii)has been independently developed by a Receiving Party (or any Affiliate
thereof) without violating any of the provisions of this License Agreement or
any other similar contract to which such Receiving Party or any of its
Representatives, is or are bound; or

 

(iii)was made available to a Receiving Party (or any Affiliate thereof), on a
non-confidential basis by a Third Party who is not prohibited from disclosing
such information to such person or entity by a legal, contractual or fiduciary
obligation to the Disclosing Party or any of its Representatives.

 

(f) Public Announcements. Except as required by Applicable Law or by the
requirements of any national securities exchange on which the securities of a
Party (or its Affiliates) are listed or traded, no Party shall make, or cause to
be made, any press release or public announcement in respect of this License
Agreement or otherwise communicate with any news media without the prior written
consent of the other Party, and the Parties shall cooperate as to the timing and
contents of any such press release or public announcement.

 

(g) Duration of Obligations. Except as otherwise provided for in this Section
5.10, Confidential Information received hereunder shall be used by each
Receiving Party and its Representatives solely in connection with such Receiving
Party fulfilling its obligations or exercising its rights under this License
Agreement. Nothing in this License Agreement shall be interpreted as vesting, in
favor of any Receiving Party or any other person or entity, any right of
ownership or other right in the Confidential Information of a Disclosing Party.
The obligations under this Section 5.10 shall survive for two (2) years after
the termination of this License Agreement.

 

 

ARTICLE 6

 

REPRESENTATIONS, WARRANTIES, AND DISCLAIMERS

 

6.1 Representations and Warranties by Amyris. Amyris hereby represents and
warrants to Novvi LLC that, as of the Effective Date,:

 

(a) Organization; Good Standing. Amyris is a corporation duly organized and in
good standing under the laws of Delaware and has full power and authority and
the legal right to own and operate its property and assets and to carry on its
business as it is now being conducted and as is contemplated to be conducted by
this License Agreement.

 

(b) Corporate Authority. Amyris has the power and authority and the legal right
to enter into this License Agreement and perform its obligations hereunder and
has taken all necessary action on its part required to authorize the execution
and delivery of this License Agreement and the performance of its obligations
hereunder.

 

(c) Binding Obligation. This License Agreement has been duly executed and
delivered by Amyris and constitutes a legal, valid, and binding obligation of
Amyris and is enforceable against it in accordance with its terms subject to the
effects of bankruptcy, insolvency or other laws of general application affecting
the enforcement of creditor rights and judicial principles affecting the
availability of specific performance and general principles of equity, whether
enforceability is considered in a proceeding at law or equity.

 

Page 20 of 37

CONFIDENTIAL

(d) Consents and Approvals. All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities
required to be obtained by Amyris in connection with the execution and delivery
of this License Agreement and the performance of its obligations hereunder have
been obtained or will be obtained prior to such performance.

 

(e) No Conflicts. The execution and delivery of this License Agreement and the
performance of Amyris’s obligations hereunder (i) do not conflict with or
violate any provision of Amyris’s articles of incorporation or bylaws, (ii) do
not conflict with, violate, or constitute a default of any contractual
obligation of Amyris, or (iii), to its knowledge, do not conflict with or
violate any requirement of Applicable Law.

 

(f) Amyris Base Technology. Amyris owns or otherwise has all necessary rights in
and to the Amyris Base Technology to grant Novvi LLC the licenses described in
Sections 2.1 and 2.3.

 

6.2 Representations and Warranties by Novvi LLC. Novvi LLC hereby represents and
warrants to Amyris that, as of the Effective Date,:

 

(a) Organization; Good Standing. Novvi LLC is a limited liability company duly
organized and in good standing under the laws of Delaware and has full power and
authority and the legal right to own and operate its property and assets and to
carry on its business as it is now being conducted and as it is contemplated to
be conducted by this License Agreement.

 

(b) Corporate Authority. Novvi LLC has the power and authority and the legal
right to enter into this License Agreement and perform its obligations hereunder
and has taken all necessary action on its part required to authorize the
execution and delivery of this License Agreement and the performance of its
obligations hereunder.

 

(c) Binding Obligation. This License Agreement has been duly executed and
delivered by Novvi LLC and constitutes a legal, valid, and binding obligation of
Novvi LLC and is enforceable against it in accordance with its terms subject to
the effects of bankruptcy, insolvency or other laws of general application
affecting the enforcement of creditor rights and judicial principles affecting
the availability of specific performance and general principles of equity,
whether enforceability is considered in a proceeding at law or equity.

 

(d) Consents and Approvals. All necessary consents, approvals and authorizations
of all regulatory and governmental authorities and other persons or entities
required to be obtained by Novvi LLC in connection with the execution and
delivery of this License Agreement and the performance of its obligations
hereunder have been obtained or will be obtained prior to such performance.

 

(e) No Conflicts. The execution and delivery of this License Agreement and the
performance of Novvi LLC’s obligations hereunder (i) do not conflict with or
violate any provision of Novvi LLC’s certificate of incorporation or Second
Amended and Restated Operating Agreement, (ii) do not conflict with, violate, or
constitute a default of any contractual obligation of Novvi LLC, or (iii), to
its knowledge, do not conflict with or violate any requirement of Applicable
Law.

 

6.3 DISCLAIMER OF WARRANTIES. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 6,
NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTY, EXPRESS OR
IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND
EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL,
OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY,
FITNESS FOR A PARTICULAR USE

Page 21 of 37

CONFIDENTIAL

OR PURPOSE, OR SAFETY, ANY WARRANTY AS TO THE ACCURACY, VALIDITY OR SCOPE OF ANY
PATENTS OR KNOW-HOW LICENSED HEREUNDER, AND ANY WARRANTY AS TO THE
NON-INFRINGEMENT OF ANY THIRD PARTY’S INTELLECTUAL PROPERTY RIGHTS THROUGH THE
PRACTICE OF ANY PATENTS OR KNOW-HOW LICENSED HEREUNDER.

 

 

ARTICLE 7

 

INDEMNIFICATION

 

7.1 Amyris’s Indemnification Obligations. Amyris will defend, indemnify, and
hold harmless Novvi LLC, its Affiliates and its and their respective members,
directors, officers, employees, and agents and their respective successors,
heirs, and permitted assigns (collectively, “Novvi LLC Indemnitees”) from and
against any and all losses, damages, liabilities, fines, costs, interest and
expenses (including reasonable attorneys’ fees and expenses) (collectively,
“Losses”) arising from a Third Party’s claim, action, suit, or demand (or
judgments or settlements arising therefrom) against a Novvi LLC Indemnity, in
each case to the extent resulting from:

 

(i)any breach by Amyris of this License Agreement;

 

(ii)the negligent, reckless, or intentionally wrongful acts or omissions on the
part of any Amyris Indemnitee in performing any activity related to this License
Agreement;

 

(iii)Amyris’s development, making, having made, offer for sale, sale, or import
of any product for which it used Novvi LLC BioFene Transformation Technology
licensed to it under Section 2.2, including any claims of product liability or
claims of infringement or misappropriation of a Third Party’s intellectual
property;

 

(iv)Novvi LLC’s making (have made), offer for sale, sale, or importing, in each
case between the Effective Date and June 1, 2013, of any Base Oil or Lubricant
for the Lubricants Market derived from BioFene using Amyris Pre-Signature Base
Technology allegedly infringing or misappropriating a Third Party’s intellectual
property but only to the extent such alleged infringement or misappropriation is
directly attributable to Novvi LLC’s adherence to the Amyris Pre-Signature Base
Technology and not to any deviation or modification from such process made by or
on behalf Novvi LLC or a permitted sublicensee of Novvi LLC, other than a
deviation or modification made by Novvi LLC at the written direction of Amyris;

 

(v)if Novvi LLC is licensed under Section 2.3 to make BioFene, Novvi LLC’s
manufacture of BioFene in either the United States of America or Brazil
allegedly infringing or misappropriating a Third Party’s intellectual property,
but only to the extent such alleged infringement or misappropriation is directly
attributable to Novvi LLC’s adherence to Amyris’s then-approved BioFene
manufacturing process licensed from Amyris as part of the licensed Amyris
BioFene Manufacturing Technology and not to any deviation or modification from
such process made by or on behalf of Novvi LLC or a permitted sublicensee of
Novvi LLC, other than a deviation or modification made by Novvi LLC at the
written direction of Amyris; or

 

(vi)Amyris’s or its Affiliates’ activities prior to the Effective Date with
regard to its use of Base Oils, Additives or Lubricants for the Lubricants
Market, including any sampling of

Page 22 of 37

CONFIDENTIAL

such products by Amyris or its Affiliates to Third Parties prior to the
Effective Date (collectively (i)-(vi), each a “Novvi LLC Third Party Claim”);

 

provided that Amyris will not defend, indemnify, or hold harmless Novvi LLC
Indemnities under this Section to the extent such Losses and/or Novvi LLC Third
Party Claim is determined to have resulted from the causes described in Section
7.2(i)-(iv).

 

7.2 Novvi LLC’s Indemnification Obligations. Novvi LLC will defend, indemnify,
and hold harmless Amyris, its Affiliates and its and their respective
shareholders, directors, officers, employees, and agents and their respective
successors, heirs, and permitted assigns (collectively, “Amyris Indemnitees”)
from and against any and all Losses arising from a Third Party’s claim, action,
suit, or demand (or judgments or settlements arising therefrom) against an
Amyris Indemnity, in each case to the extent resulting from:

 

(i)any breach by Novvi LLC of this License Agreement;

 

(ii)the negligent, reckless, or intentionally wrongful acts or omissions on the
part of any Novvi LLC Indemnitee in performing any activity related to this
License Agreement;

 

(iii)except as set forth in Section 7.1(iv), Novvi LLC’s development, making
(have made), offer for sale, sale, or import of any Base Oil, Additive, or
Lubricant derived from BioFene, including any claims of product liability or
claims of infringement or misappropriation of a Third Party’s intellectual
property; or

 

(iv)except as set forth in Section 7.1(v), Novvi LLC’s manufacture of BioFene
allegedly infringing or misappropriating a Third Party’s intellectual property
(collectively (i)-(iv), each an “Amyris Third Party Claim”);

 

provided that Novvi LLC will not defend, indemnify, or hold harmless Amyris
Indemnities under this Section to the extent such Losses and/or Amyris Third
Party Claim is determined to have resulted from the causes described in Section
7.1(i)-(vi).

 

7.3 Indemnification Procedures. The Parties’ obligations under Sections 7.1 and
7.2 shall be governed by and contingent upon the following:

 

(a) Notice of Claim. All indemnification claims in respect of a Novvi LLC
Indemnitee or Amyris Indemnitee shall be made solely by Novvi LLC or Amyris, as
applicable (each of Novvi LLC or Amyris in such capacity, the “Indemnified
Party”). Promptly after a Novvi LLC Indemnitee or an Amyris Indemnitee receives
notice of a threatened, pending, or actual Novvi LLC Third Party Claim or Amyris
Third Party Claim (a “Third Party Claim”), the applicable Indemnified Party
shall give written notice of the Third Party Claim to the Party to whom that
Indemnified Party is entitled to look for indemnification pursuant to this
Article 7 (the “Indemnifying Party”). Such written notice (an “Indemnification
Claim Notice”) shall contain a description of the claim, the nature and amount
of such Loss (to the extent that the nature and amount of such Loss is known at
such time), and the basis for indemnification under this Article 7. An
Indemnified Party’s delay in providing, or failure to provide, an
Indemnification Claim Notice will not relieve the Indemnifying Party of its
obligations under this Article 7 for the Third Party Claim, except to the extent
it can demonstrate that such delay or failure materially adversely affects the
ability of the Indemnifying Party to defend the Third Person Claim, to cure the
breach (if applicable) giving rise to such Third Person Claim, or minimize the
applicable Loss. The Indemnified Party shall also furnish promptly to the
Indemnifying Party copies of all papers and official documents received in
respect of the Third Party Claim.

 

Page 23 of 37

CONFIDENTIAL

(b) Assumption of Defense. At its option, the Indemnifying Party may assume the
defense of the Third Party Claim by giving written notice to the Indemnified
Party within thirty (30) days after receipt of the Indemnification Claim Notice
(an “Assumption Notice”). Such assumption shall not be construed as an
acknowledgement of liability or a waiver of any defenses by the Indemnifying
Party (and the Indemnifying Party shall be reimbursed by the Indemnified Party
in the case in which the Indemnified Party is not liable under this Article 7).

 

(c) Control of Defense by the Indemnifying Party. Upon giving a timely
Assumption Notice to the Indemnified Party, the Indemnifying Party:

 

(i)has the exclusive right, at its own expense and by counsel of its choosing
(but who is reasonably satisfactory to the Indemnified Party), conduct and
control the defense and the disposition or, subject to Subsection (d) below,
settlement of the Third Party Claim (including all decisions relative to
litigation, appeal, and settlement);

 

(ii)will conduct the defense and, if applicable, settlement of such Third Person
Claim in a reasonable and diligent manner;      (iii)will keep the Indemnified
Party informed on a reasonable and timely basis as to the status of such Third
Party Claim to the extent the Indemnified Party is not participating in the
defense;     (iv)is not liable for the fees or expenses of counsel hired by the
Indemnified Party in connection with the defense of the Third Party Claim
(except in the case where the interests of the Indemnified Party and
Indemnifying Party are sufficiently adverse to prohibit the representation by
the same counsel of both Parties under Applicable Law, ethical rules or
equitable principles); and      (v)is not liable for any other expenses
subsequently incurred by the Indemnified Party in connection with such defense,
other than the Indemnified Party’s reasonable out-of-pocket costs incurred in
cooperating with the Indemnifying Party per Subsection (e) below.

 

(d) Settlement by the Indemnifying Party. If an Indemnifying Party has assumed
the defense of a Third Party Claim under Subsection (b) above, the Indemnifying
Party may not settle or compromise a Third Party Claim without the prior written
consent of the Indemnified Party (not to be unreasonably withheld, conditioned,
or delayed) unless such settlement or compromise (i) involves no payment
(whether by cash, securities or other instrument), assignment, obligation,
granting of a license, or admission of fault or wrongdoing by, or injunctive or
other equitable relief against, the Indemnified Party and (ii) the Indemnified
Party receives a comprehensive general release of all claims from the applicable
Third Party. In no event will an Indemnifying Party, without the written consent
of the other Party, be entitled to settle any Third Party Claim by granting a
license or covenant not to sue under or with respect to the Patents or other
intellectual property rights owned by the other Party. Furthermore, in the case
of a Novvi LLC Third Party Claim under Section 7.1(v), Novvi LLC agrees that, if
Amyris has assumed the defense of such Third Party Claim under Subsection (b)
above, Novvi LLC will work together with Amyris in good faith should Amyris
reasonably determine that settling such matter and/or the Parties avoiding
additional such Third Party Claims is to modify the BioFene manufacturing
process that is both licensed to Novvi LLC and used by Amyris for its own
BioFene manufacturing.

 

(e) Indemnified Party’s Cooperation. If an Indemnifying Party has assumed the
defense of a Third Party Claim under Subsection (b), the Indemnified Party
shall, and shall cause each of its Novvi

 

Page 24 of 37

CONFIDENTIAL

LLC Indemnitees or Amyris Indemnitees (as applicable), to reasonably cooperate
with the Indemnifying Party, mitigate potential Losses, and furnish such
records, information and testimony, provide such witnesses and attend such
conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include
access during normal business hours by the Indemnifying Party to, and reasonable
retention by the Indemnified Party of, records and information that are
reasonably relevant to such Third Party Claim and making the Indemnified Party
and its Novvi LLC Indemnitees or Amyris Indemnitees (as applicable) available on
a mutually convenient basis to provide additional information and explanation of
any records or information provided. In addition, if an Indemnifying Party has
assumed the defense of a Third Party Claim under Subsection (b), the Indemnified
Party may employ separate counsel to participate in the defense of such Third
Party Claim, but such counsel will be at the Indemnified Party’s sole expense. 
  

 

(f) Expenses. Any reasonable and verifiable costs and expenses incurred by the
Indemnified Party in connection with a Third Party Claim and reimbursable as set
forth this Article 7 shall be reimbursed on a calendar quarter basis by the
Indemnifying Party, without prejudice to the Indemnifying Party’s right to
contest the Indemnified Party’s right to indemnification and subject to refund
in the event the Indemnifying Party is ultimately held not to be obligated to
defend, indemnify, or hold harmless the Indemnified Party under this Article 7.

 

(g) Breach by the Indemnifying Party of its Article 7 Obligations. If the
Indemnifying Party denies its obligations under this Article 7, fails to timely
provide an Assumption Notice with regard to a Third Party Claim, or fails to
diligently defend, indemnify, and hold harmless such Third Party Claim
throughout the period that such claim exists, then its right to defend that
Third Party Claim shall immediately terminate upon written notice from the
Indemnified Party, and the Indemnified Party may assume the defense of, and
settle, such claim with counsel of its own choice and on such terms as it deems
reasonably appropriate, with written notice to the Indemnifying Party but
without any obligation to obtain the consent of the Indemnifying Party. The
Indemnifying Party will be obligated to indemnify and hold harmless the
Indemnified Party for the costs of such defense and settlement if it is
determined that the Indemnifying Party breached its obligations under this
Article 7 with regard to such Third Party Claim and that the Third Party Claim
is subject to the indemnification provisions of this Article 7. 

 

7.4 Disclaimer of Consequential Damages. EXCEPT FOR WILLFUL MISCONDUCT, NEITHER
PARTY WILL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL,
EXEMPLARY OR PUNITIVE OR SPECIAL DAMAGES OF ANY KIND ARISING OUT OF OR IN
CONNECTION WITH THIS LICENSE AGREEMENT, INCLUDING, BUT NOT LIMITED TO, LOST
PROFITS, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT,
TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE), EVEN IF SUCH PARTY
WAS ADVISED OR OTHERWISE AWARE OF THE LIKELIHOOD OF SUCH DAMAGES AND REGARDLESS
OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED, HOWEVER, THAT THE
FOREGOING DISCLAIMER DOES NOT APPLY TO OR LIMIT EITHER PARTY’S INDEMNIFICATION
OBLIGATIONS UNDER THIS ARTICLE 7 WITH REGARD TO THIRD PERSON CLAIMS.

 

7.5 Insurance. While a Party’s license(s) under this License Agreement are in
effect and for three (3) years thereafter, such Party shall have and maintain
such type and amounts of liability insurance covering its activities under this
License Agreement as is normal and customary in such Party’s industry for
parties similarly situated, and such Party shall upon request provide the other
Party a certificate confirming such insurance is in place.

 

 

ARTICLE 8

Page 25 of 37

CONFIDENTIAL

DISPUTE RESOLUTION

 

8.1 Governing Law. This License Agreement shall be governed by and construed,
interpreted and enforced in accordance with the laws of the State of New York,
without giving effect to the principles of conflicts of law or of choice of law
thereof (other than Sections 5-1401 and 5-1402 of the New York General
Obligations Law, which shall apply to this License Agreement). The Parties agree
to exclude the application to this License Agreement of the United Nations
Convention on Contracts for the International Sale of Goods.

 

8.2 Binding Arbitration.

 

(a) Informal Resolution. In the event of any dispute between the Parties
involving this License Agreement, such dispute shall be governed by and resolved
subject to this Article 8. Notwithstanding anything contained in this License
Agreement, the Parties undertake to use their reasonable efforts to amicably
resolve by mutual negotiation of their chief executive officers (or their
designees) any disputes between themselves involving this License Agreement.

 

(b) Submit to AAA Arbitration. In case such mutual agreement is not reached
under Subsection (a) above within thirty (30) days after submission of the
dispute to the Parties’ chief executive officers (or their designees), either
Party, subject to Subsection (i) below with regard to Patent disputes, may refer
the dispute to binding arbitration under the then-existing rules (“Arbitration
Rules”) of the American Arbitration Association (“Arbitration Chamber”), which
will exclusively and finally settle such dispute. The Arbitration Rules are
deemed to be incorporated by reference into this License Agreement, except as
such Arbitration Rules may be modified herein or by subsequent mutual agreement
by the Parties. The arbitration proceedings filed based on this License
Agreement shall be administered by the Arbitration Chamber. Any such arbitration
shall be conducted in accordance with, and subject in all respect to, the
following: For the avoidance of doubt, this Article 8 equally binds all Parties
to this License Agreement, and such Parties hereby agree to submit to and comply
with all the terms and conditions of this Article 8, which shall be in full
force and effect irrevocably, and subject to specific performance. Unless
otherwise agreed in writing, the Parties shall continue to diligently perform
their respective duties and obligations under this License Agreement while an
arbitral proceeding is pending.

 

(c) Selection of the Arbitral Tribunal. Each arbitration under this Article 8
will be settled by a panel of three (3) arbitrators. Each Party shall nominate
one arbitrator in accordance with the Arbitration Rules, and the two arbitrators
so nominated shall nominate jointly a third arbitrator, who shall serve as the
chair of the arbitral tribunal (“Arbitral Tribunal”), within fifteen (15) days
from the receipt of a communication from the Arbitration Chamber by the two
previously nominated arbitrators. If any arbitrator has not been nominated
within the time limits specified herein and/or in the Arbitration Rules, as
applicable, such appointment shall be made by the Arbitration Chamber upon the
written request of either Party within fifteen (15) days of such request. If at
any time a vacancy occurs in the Arbitral Tribunal, the vacancy shall be filled
in the same manner and subject to the same requirements as provided for the
original appointment to that position.

 

(d) Location of the Arbitration. The place of arbitrations shall be the city of
New York, New York, U.S.A., where the award(s) shall be rendered, and all
arbitrations shall be conducted in English.

 

(e) Arbitration Decision. An arbitration award shall be final, unappealable and
binding on the Parties, their successors and assignees, who agree to comply with
it and spontaneously and expressly

Page 26 of 37

CONFIDENTIAL

waive any form of appeal, except for the request for fraud, correction of
material error or clarification of uncertainty, doubt, contradiction or omission
of the arbitration award. If necessary, an arbitration award may be performed in
any court that has jurisdiction or authority over a Party or its assets. The
arbitration award will include the distribution of costs, including reasonable
attorney’s fees and reasonable expenses as the Arbitral Tribunal sees fit.

 

(f) Exclusive Dispute Resolution Process; Exceptions. The Parties are fully
aware of all terms and effects of the arbitration provisions herein agreed upon
and irrevocably agree that arbitration hereunder is the only form of resolution
of any disputes arising between themselves involving this License Agreement,
except as expressly set forth to the contrary in this Section 8.2. Without
prejudice to the validity of these arbitration provisions, either Party may seek
judicial assistance and/or relief, if and when necessary, for the sole purposes
of:

 

(i)executing obligations that admit, forthwith, specific performance;

 

(ii)obtaining coercive or precautionary measures or procedures of a preventive,
provisional or permanent nature, as security for the arbitration to be commenced
or already in course between the Parties and/or to ensure the existence and
efficacy of the arbitration proceeding; or

 

(iii)fraud, correction of material error or clarification of uncertainty, doubt,
contradiction or omission of the arbitration award; or

 

(iv)obtaining measures of a mandatory and specific nature;

 

it being understood that, upon accomplishment of the mandatory or specific
enforcement procedures sought, the dispute shall be returned to the Arbitral
Tribunal to be established or already established, as applicable, full and
exclusive authority to decide on all and any issues, whether related to
procedure or merit, which has caused the mandatory or specific enforcement
claim, with the respective judicial proceeding being interrupted until the
partial or final decision of the Arbitral Tribunal. The Parties agree that
irreparable damage would occur in the event any provision of this License
Agreement was not performed in accordance with the terms hereof and that the
Parties shall be entitled to specific performance of the terms hereof, in
addition to any other remedy at law or in equity.

 

For the measures indicated in (i) through (iv) above, the Parties elect any
state or U.S. federal court located in the city of New York, New York, U.S.A.,
to the exclusion of any other courts, and the Parties hereby irrevocably submit
to the exclusive jurisdiction of any state or U.S. federal court located within
the City of New York, New York, U.S.A. over any such action. The Parties hereby
irrevocably waive, to the fullest extent permitted by Applicable Law, any
objection which they may now or hereafter have to the laying of venue of any
such action brought in such court or any defense of inconvenient forum for the
maintenance of such action. The filing of any measure under this Subsection (f)
does not entail any waiver to the arbitration under this Article 8 or to the
full jurisdiction of the Arbitral Tribunal.

 

(g) Confidentiality. The Parties and their respective Representatives, the
witnesses, the Arbitral Tribunal, the Arbitration Chamber and its secretariat
agree to treat the existence, content, awards and decisions relating to an
arbitration proceeding hereunder, together with all the materials, information
and testimony used therein or created for the purposes thereof, as well as other
documents produced or disclosed by each Party during the arbitration proceeding,
as Confidential Information of the other Party, subject to the obligations and
exceptions in Section 5.10.

Page 27 of 37

CONFIDENTIAL

(h) Consolidation with Second Amended and Restated Operating Agreement
Arbitrations. In order to facilitate the comprehensive resolution of related
disputes between the Parties under this License Agreement and the Second Amended
and Restated Operating Agreement, any or all such disputes may be brought in a
single arbitration under the following circumstances and conditions: If one or
more arbitrations are already pending between the Parties hereunder or under the
Second Amended and Restated Operating Agreement and a new dispute arises between
the Parties under any of said agreements or a subsequently filed arbitration is
brought between the Parties under any said agreements, then a Party may request
that such new dispute or any subsequently filed arbitration be consolidated into
any prior pending arbitration. Within twenty (20) days of a request to
consolidate, the Parties shall select one of the prior pending arbitrations into
which the new dispute or subsequently filed arbitration may be consolidated
(“Selected Arbitration”). If the Parties are unable to agree on the Selected
Arbitration within such twenty (20) day period, then the Arbitration Chamber
shall indicate the Selected Arbitration within twenty (20) days of a written
request by a Party. If the Arbitration Chamber fails to indicate the Selected
Arbitration within the 20-day time limit indicated above, the arbitration first
initiated shall be considered the Selected Arbitration. The new dispute or
subsequently filed arbitration shall be so consolidated, provided that the
Arbitral Tribunal for the Selected Arbitration determines that: (i) the new
dispute or subsequently filed arbitration presents significant issues of law or
fact common with those in the Selected Arbitration; (ii) neither Party would be
unduly harmed in the new dispute or in the Selected Arbitration; and (iii)
consolidation under these circumstances would not result in undue delay for the
Selected Arbitration. Any such order of consolidation issued by the Arbitral
Tribunal shall be final and binding upon the Parties. The Parties waive any
right they may have to appeal or to seek interpretation, revision or annulment
of such order of consolidation under the Arbitration Rules and/or the Applicable
Law in any court. The Arbitral Tribunal for the Selected Arbitration into which
a new dispute or subsequently filed arbitration is consolidated shall serve as
the Arbitral Tribunal for the consolidated arbitration.

 

(i) Exception for Patent-related Disputes. In the event that a dispute arises
with respect to the inventorship, scope, ownership, validity, enforceability,
revocation or infringement of a Patent and such dispute cannot be resolved by
the Parties in accordance with Subsection (a) above, then, unless otherwise
agreed by the Parties in writing, such dispute will not be submitted to
arbitration under this Section 8.2, and either Party may initiate litigation
solely in a court of competent jurisdiction in the country of issuance of the
Patent that is the subject of the dispute.

 

8.3 Service of Process. Each Party agrees that, in any dispute, claim, action,
suit or proceeding between the Parties in connection with this License Agreement
that, per this License Agreement or Applicable Law, may be brought in a court,
process may be served on a Party anywhere in the world, whether within or
without the jurisdiction of any such court. Without limiting the foregoing, each
Party agrees that service of process on such Party at the location, and as
provided, in Section 10.10 shall be deemed effective service of process on such
Party. Nothing herein shall affect the right of either Party to serve legal
process in any other manner permitted by Applicable Law or at equity.

 

8.4 Waiver of Jury Trial. WITH RESPECT TO ANY DISPUTE, CLAIM, ACTION, SUIT OR
PROCEEDING BETWEEN THE PARTIES IN CONNECTION WITH THIS LICENSE AGREEMENT THAT,
PER THIS LICENSE AGREEMENT OR APPLICABLE LAW, MAY BE BROUGHT IN A COURT, EACH OF
THE PARTIES HEREBY IRREVOCABLY WAIVES AND RELEASES TO THE OTHER ITS RIGHT TO A
TRIAL BY JURY AND AGREES THAT IT WILL NOT SEEK A TRIAL BY JURY IN ANY SUCH
DISPUTE, CLAIM, ACTION, SUIT OR PROCEEDING.

 

 

ARTICLE 9

Page 28 of 37

CONFIDENTIAL

TERM AND TERMINATION

 

9.1 Term of the License Agreement. The term of this License Agreement shall
commence on the Effective Date and shall continue in full force and effect until
the expiration or termination of all licenses granted pursuant to Sections 2.1,
2.2, and 2.3.

 

9.2 Initial Term of the Licenses.

 

(a) Novvi LLC’s Licenses in Section 2.1. The licenses granted to Novvi LLC in
Section 2.1 will be effective as of the Effective Date and will continue, unless
earlier terminated per this Article 9, until (i) with respect to any Know-How in
the Amyris Base Technology, the twentieth (20th) anniversary of the Effective
Date and (ii) with respect to each Patent in the Amyris Base Technology, the
twentieth (20th) anniversary of the Effective Date or the expiration or
invalidation of the applicable Patent, whichever is sooner.

 

(b) Novvi LLC’s License under Section 2.3. If Amyris grants Novvi LLC a license
under Section 2.3, then such license will be effective upon the date Amyris
grants it per the terms of Section 2.3 and will continue, unless earlier
terminated per this Article 9, until (i) with respect to any Know-How in the
Amyris BioFene Manufacturing Technology, the twentieth (20th) anniversary of the
Effective Date and (ii) with respect to each Patent in the Amyris BioFene
Manufacturing Technology, the twentieth (20th) anniversary of the Effective Date
or the expiration or invalidation of the applicable Patent, whichever is sooner.

 

(c) Amyris’s License in Section 2.2. The license granted to Amyris in Section
2.2 will be effective as of the Effective Date and will continue, unless earlier
terminated per this Article 9, until (i) with respect to any Know-How in the
Novvi LLC BioFene Transformation Technology, the twentieth (20th) anniversary of
the Effective Date and (ii) with respect to each Patent in the Novvi LLC BioFene
Transformation Technology, the twentieth (20th) anniversary of the Effective
Date or the expiration or invalidation of the applicable Patent, whichever is
sooner.

 

9.3 Extend the Term of Licenses. If a license granted to Novvi LLC in Section
2.1 or under Section 2.3, or to Amyris under Section 2.2, has not been earlier
terminated under this Article 9, the Parties agree to decide, no later than the
eighteenth (18th) anniversary of the Effective Date, whether or not to extend
the term of such license(s) set forth in Section 9.2(a)-(c) beyond the twentieth
(20th) anniversary of the Effective Date. If the Parties agree to extend the
term of such licenses to Novvi LLC and/or Amyris, such extension shall be set
forth in writing signed by both Parties, but such licenses will still be subject
to earlier termination under this Article 9.

 

9.4 Expiration of a Novvi LLC License. Upon the expiration of the term (as may
be extended per Section 9.3) of a license granted to Novvi LLC in Section 2.1 or
under Section 2.3 if such license was not earlier terminated,

 

 (i)such expired license will immediately cease;     (ii)Novvi LLC will have no
rights to or under any intellectual property or Confidential Information of
Amyris, unless, at the time, it continues to have another unexpired and
un-terminated license(s) under this License Agreement, in which case such
unexpired and un-terminated license(s) of Novvi LLC will continue unaffected, as
will this License Agreement with regard to such unexpired and un-terminated
license(s);

 

Page 29 of 37

CONFIDENTIAL

(iii)any sublicense Novvi LLC may have granted an Affiliate or Third Party under
the expired license automatically terminates;

 

(iv)Section 2.1 or 2.3 (whichever is applicable to the expired license) and
Article 3 (if the expired license had been granted under Section 2.1)
automatically terminate;

 

(v)Novvi LLC, if upon such expiration it has no more licenses under this License
Agreement, will remain obligated to perform its obligations in Articles 5, 7, 8,
and 10; and

 

(vi)Amyris’s license under Section 2.2 will continue unaffected, as will this
License Agreement with regard to such license.

 

9.5 Expiration of Amyris License. Upon the expiration of the term (as may be
extended per Section 9.3) of the license granted to Amyris in Section 2.2,

 

 (i)such expired license will immediately cease;     (ii)Amyris will have no
rights to or under any intellectual property or Confidential Information of
Novvi LLC;

 

(iii)any sublicense Amyris may have granted an Affiliate or Third Party under
the expired license automatically terminates;

 

(iv)Section 2.2 automatically terminates;

 

(v)Amyris will remain obligated to perform its obligations pursuant to this
License Agreement; and

 

(vi)Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected, as
will this License Agreement with regard to such licenses.

 

9.6 Uncured Material Breach by Novvi LLC. If Novvi LLC materially breaches this
License Agreement and does not cure such breach within sixty (60) days after
receiving written notice from Amyris of such breach, Amyris may, with another
written notice to Novvi LLC, immediately terminate all of the licenses granted
to Novvi LLC under this License Agreement. If, per this Section, Amyris
terminates Novvi LLC’s licenses under this License Agreement, then, upon such
termination,:

 

(i)Novvi LLC will have no rights to or under any intellectual property or
Confidential Information of Amyris;

 

(ii)any sublicense Novvi LLC may have granted an Affiliate or Third Party
automatically terminates;

 

(iii)Sections 2.1 and 2.3 and Article 3 automatically terminate;

 

(iv)Novvi LLC will remain obligated to perform its obligations in Articles 5, 7,
8, and 10; and

 

(v)Amyris’s license under Section 2.2 will continue unaffected, as will this
License

Page 30 of 37

CONFIDENTIAL

Agreement with regard to such license.

 

Termination under this Section is not Amyris’s exclusive remedy for a Novvi LLC
breach but is in addition to any other rights or remedies Amyris may have under
this License Agreement or Applicable Law for such breach.

 

9.7 Uncured Material Breach by Amyris. If Amyris materially breaches this
License Agreement and does not cure such breach within sixty (60) days after
receiving written notice from Novvi LLC of such breach, Novvi LLC may, with
another written notice to Amyris, immediately terminate the license granted to
Amyris under this License Agreement. If, per this Section, Novvi LLC terminates
Amyris’s license under this License Agreement, then, upon such termination,:

 

(i)Amyris will have no rights to or under any intellectual property or
Confidential Information of Novvi LLC;

 

(ii)any sublicense Amyris may have granted an Affiliate or Third Party under the
license automatically terminates;

 

(iii)Section 2.2 automatically terminates;

 

(iv)Amyris will remain obligated to perform its obligations in Articles 5, 7, 8,
and 10; and

 

(v)Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected, as
will this License Agreement with regard to such licenses.

 

9.8 Event of Dissolution of Novvi LLC. Upon the occurrence of an event described
in Section 11.03 of the Second Amended and Restated Operating Agreement that
triggers dissolution of Novvi LLC and Novvi LLC is dissolved and wound up:

 

(i)all of the licenses granted to Novvi LLC under this License Agreement, if not
previously expired or terminated, will automatically terminate;

 

(ii)Novvi LLC will have no rights to or under any intellectual property or
Confidential Information of Amyris;

 

(iii)any sublicense Novvi LLC may have granted an Affiliate or Third Party
automatically terminates; and

 

(iv)Sections 2.1 and 2.3 and Article 3 automatically terminate (if not
previously terminated).

 

9.9 Insolvency Event for Novvi LLC. Upon the occurrence of an Insolvency Event
for Novvi LLC:

 

(i)all of the licenses granted to Novvi LLC under this License Agreement, if not
previously expired or terminated, will automatically terminate;

 

(ii)Novvi LLC will have no rights to or under any intellectual property or
Confidential Information of Amyris;

Page 31 of 37

CONFIDENTIAL

(iii)any sublicense Novvi LLC may have granted an Affiliate or Third Party
automatically terminates;

 

(iv)Sections 2.1 and 2.3 and Article 3 automatically terminate (if not
previously terminated or expired);

 

(v)Novvi LLC will remain obligated to perform its obligations in Articles 5, 7,
8, and 10; and

 

(vi)Amyris’s license under Section 2.2 will continue unaffected per Section 2.6,
as will this License Agreement with regard to such license.

 

9.10 Insolvency Event for Amyris. Upon the occurrence of an Insolvency Event for
Amyris:

 

(i)the license granted to Amyris under this License Agreement, if not previously
expired or terminated, will automatically terminate;

 

(ii)Amyris will have no rights to or under any intellectual property or
Confidential Information of Novvi LLC;

 

(iii)any sublicense Amyris may have granted an Affiliate or Third Party under
the license automatically terminates;

 

(iv)Section 2.2 automatically terminates (if not previously terminated or
expired);

 

(v)Amyris will remain obligated to perform its obligations in Articles 5, 7, 8,
and 10; and

 

(vi)Novvi LLC’s licenses under Sections 2.1 and 2.3 will continue unaffected per
Section 2.6, as will this License Agreement with regard to such licenses.

 

9.11 Surviving Provisions. Notwithstanding anything to the contrary, in the
event that this License Agreement expires or is terminated, the following
provisions, and the Parties’ respective rights and obligations under them, will
survive such circumstances: Article 1, Sections 5.1, 5.2, 5.3, 5.4, 5.8, and
5.10 (for the time period set forth in Section 5.10), Article 7, Article 8, and
Article 10, and this Section.

 

 

ARTICLE 10

 

MISCELLANEOUS

 

10.1 Compliance with Law. With respect to the performance of this License
Agreement and the activities contemplated by this License Agreement, each Party
shall comply with all Applicable Laws.

 

10.2 No Conflicting Rights. Neither Party will grant any license, right, or
encumbrance to any Affiliate or Third Party that would conflict with the
licenses or rights granted hereunder or enter into any agreement that would
impair such Party’s ability to perform its obligations under this License
Agreement.

Page 32 of 37

CONFIDENTIAL

10.3 Further Assurances.  After the Effective Date, each of the Parties shall
execute and deliver such additional documents, certificates, and instruments and
perform such additional acts, as may be reasonably requested and necessary or
appropriate to carry out the purposes and intent and all of the provisions of
this License Agreement and to consummate all of the transactions contemplated by
this License Agreement.

 

10.4 Expenses.  Each Party shall be responsible for and bear all of its own
costs and expenses (including but not limited to any attorneys’ fees,
accountants’ fees, or financial advisors’ fees or any prior commitment in
respect thereof) with regard to the negotiation and consummation of the
transactions contemplated by this License Agreement. 

 

10.5 Relationship of the Parties.  Each Party is an independent contractor
relative to the other Party under this License Agreement. This License Agreement
is not a partnership agreement, and nothing in this License Agreement shall be
construed to establish a relationship of co-partners or joint venturers between
the Parties.  No employee or representative of a Party, per this License
Agreement, shall have any authority to bind or obligate the other Party or to
create or impose any contractual or other liability on the other Party.

 

10.6 No Third Party Beneficiaries. Except with regard to the Novvi LLC
Indemnitees and Amyris Indemnitees under Article 7 and Total with regard to
Section 4.1, all rights, benefits, and remedies under this Licensee Agreement
are solely intended for the benefit of the Parties and their respective
permitted successors and assigns. No Third Party (except Novvi LLC Indemnitees
and Amyris Indemnitees with regard to their rights, benefits and remedies
Article 7 and Total with regard to Section 4.1) shall have any rights whatsoever
to enforce any obligation contained this License Agreement, seek a benefit or
remedy for any breach, or take any other action relating to this License
Agreement under any legal or equitable theory.

 

10.7 Amendments and Waivers. This License Agreement may be amended or waived if,
and only if, such amendment or waiver is in writing and signed, in the case of
an amendment, by all Parties or, in the case of a waiver, by the Party against
whom the waiver is to be effective. No failure or delay by any Party in
exercising any right, power or privilege hereunder (other than a failure or
delay beyond a period of time specified herein) shall operate as a waiver
thereof; nor shall any waiver by a Party of any term or condition of this
License Agreement in any one or more instances, be deemed to be or construed as
a waiver of the same or any other term or condition of this License Agreement on
any future occasion.

 

10.8 Assignment. Other than its sublicensing rights under Section 2.1 and
potentially under Section 2.3, Novvi LLC may not assign or delegate, in whole or
in part, this License Agreement or any of its rights or obligations under this
License Agreement without the prior written consent of Amyris, such consent not
to be unreasonably withheld. In addition to its sublicense rights under Section
2.2, Amyris may, without Novvi LLC’s consent, assign or delegate, in whole or in
part, this License Agreement or any of its rights or obligations under this
License Agreement to (i) an Affiliate but only while such Affiliate remains an
Affiliate and if Amyris remains responsible for such Affiliate’s performance of
the License Agreement, (ii) a buyer of all or substantially all of Amyris’s
assets as long as such buyer delivers a writing expressly agreeing to assume
such performance, or (iii) a surviving entity with whom Amyris is merged as long
as such surviving entity delivers a writing expressly agreeing to assume such
performance. Any assignment or delegation or attempted assignment or delegation
not in accordance with this Section 10.8 shall be null and void. This License
Agreement shall be binding upon and inure solely to the benefit of the Parties
and their permitted successors and assigns.

 

10.9 Severability.  If any provision of this License Agreement should be held
invalid, illegal

Page 33 of 37

CONFIDENTIAL

or unenforceable in any jurisdiction, the Parties shall negotiate in good faith
a valid, legal and enforceable substitute provision that most nearly reflects
the original intent of the Parties and all other provisions hereof shall remain
in full force and effect in such jurisdiction and shall be liberally construed
in order to carry out the intentions of the Parties as nearly as may be
possible. Such invalidity, illegality or unenforceability shall not affect the
validity, legality or enforceability of such provision in any other
jurisdiction. Nothing in this License Agreement shall be interpreted so as to
require a Party to violate any Applicable Law.

 

10.10 Notices.  All notices, consents, claims, waivers, requests and other
communications hereunder shall be in writing and shall be delivered in person,
sent by overnight courier (e.g., Federal Express), facsimile transmission or
posted by registered or certified mail, return receipt requested, with postage
prepaid, to the following address of each Party:

 

If to Amyris:

 

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, CA 94608

Attn: General Counsel

 

If to Novvi LLC:

 

Novvi LLC

5885 Hollis Street

Emeryville, CA 94608

Attn: President

 

with a copy to, but only for such time as Cosan US remains a member of Novvi
LLC, (but which shall not constitute notice):

 

Cosan US, Inc.

2711 Centerville Road, Suite 400

Wilmington, Delaware 19808

Attn: President

 

Cosan Lubrificantes e Especialidades S.A.

Rua Victor Civita, 77 – Edifício 6 / Bloco 1 – 4º andar

Barra da Tijuca – Rio de Janeiro – RJ

CEP 22775-905 Brazil

Attn: Chief Executive Officer

 

or to such other address or addresses as each Party may from time-to-time
designate by notice as provided herein.  Any such notice shall be deemed given
(i) when actually received when so delivered personally or by overnight courier
or (ii) if mailed, other than during a period of general discontinuance or
disruption of postal service due to strike, lockout or otherwise, on the fifth
(5th) day after its postmarked date thereof or (iii) if sent by facsimile
transmission on the date sent if such day is a business day or the next
following business day if such day is not a business day. 

 

10.11 Entire Agreement.  This License Agreement sets forth all the covenants,
promises, agreements, warranties, representations, conditions and understandings
between the Parties and supersedes and terminates all prior agreements and
understandings between the Parties relating to the

Page 34 of 37

CONFIDENTIAL

subject matter hereof.  There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the Parties other than as set forth in this License Agreement
that relate to the subject matter hereof. 

 

10.12 Interpretation.  When a reference is made in this License Agreement to
Articles, Sections, or Subsections, such reference shall be to an Article,
Section, or Subsection to this License Agreement unless otherwise indicated. 
The words “include,” “includes,” and “including” when used herein shall be
deemed in each case to be followed by the words “without limitation” and shall
not be construed to limit any general statement that it follows to the specific
or similar items or matters immediately following it.  The headings and captions
in this License Agreement are for convenience and reference purposes only and
shall not be considered a part of or affect the construction or interpretation
of any provision of this License Agreement.  Words of any gender include the
other gender, and words using the singular or plural number also include the
plural or singular number, respectively.  Each Party acknowledges and agrees it
has had the opportunity to draft, review and edit the language of this License
Agreement and that no presumption for or against any Party arising out of
drafting all or any part of this License Agreement will be applied in any
controversy, claim or dispute relating to, in connection with or involving this
License Agreement. Accordingly, the Parties hereby waive the benefit of any rule
of Applicable Law, including California Civil Code Section 1654 and any
successor or amended statute, or any legal decision that would require that in
cases of uncertainty, the language of a contract should be interpreted most
strongly against the party who drafted such language.

 

10.13 Counterparts.  This License Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This License Agreement
may be executed by facsimile or other electronic signatures (including exchange
of emailed pdf), and such signatures shall be deemed to bind each Party as if
they were original signatures.

 

THIS LICENSE AGREEMENT is hereby executed effective as of the Effective Date by
the authorized representatives of the Parties.

 

AMYRIS, INC.   NOVVI LLC               /s/ R. Asadorian                   By: R.
Asadorian   By:                 Title: CFO   Title:                            
                                          By:                       Title:    

 

 

Page 35 of 37

CONFIDENTIAL

subject matter hereof.  There are no covenants, promises, agreements,
warranties, representations, conditions or understandings, either oral or
written, between the Parties other than as set forth in this License Agreement
that relate to the subject matter hereof. 

 

10.12 Interpretation.  When a reference is made in this License Agreement to
Articles, Sections, or Subsections, such reference shall be to an Article,
Section, or Subsection to this License Agreement unless otherwise indicated. 
The words “include,” “includes,” and “including” when used herein shall be
deemed in each case to be followed by the words “without limitation” and shall
not be construed to limit any general statement that it follows to the specific
or similar items or matters immediately following it.  The headings and captions
in this License Agreement are for convenience and reference purposes only and
shall not be considered a part of or affect the construction or interpretation
of any provision of this License Agreement.  Words of any gender include the
other gender, and words using the singular or plural number also include the
plural or singular number, respectively.  Each Party acknowledges and agrees it
has had the opportunity to draft, review and edit the language of this License
Agreement and that no presumption for or against any Party arising out of
drafting all or any part of this License Agreement will be applied in any
controversy, claim or dispute relating to, in connection with or involving this
License Agreement. Accordingly, the Parties hereby waive the benefit of any rule
of Applicable Law, including California Civil Code Section 1654 and any
successor or amended statute, or any legal decision that would require that in
cases of uncertainty, the language of a contract should be interpreted most
strongly against the party who drafted such language.

 

10.13 Counterparts.  This License Agreement may be executed in any number of
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This License Agreement
may be executed by facsimile or other electronic signatures (including exchange
of emailed pdf), and such signatures shall be deemed to bind each Party as if
they were original signatures.

 

THIS LICENSE AGREEMENT is hereby executed effective as of the Effective Date by
the authorized representatives of the Parties.

 

AMYRIS, INC.   NOVVI LLC                   /s/ Jeffrey Brown             By:    
By: Jeffrey Brown               Title:     Title: President & CEO              
                              /s/ Jason R. Wells                     By: Jason
R. Wells                     Title: CTO  

 

 

 

Page 36 of 37

CONFIDENTIAL

Exhibit A

 

Definition of European Union

 

 

 

1.Austria

2.Belgium

3.Bulgaria

4.Croatia

5.Cyprus

6.Czech Republic

7.Denmark

8.Estonia

9.Finland

10.France

11.Germany

12.Greece

13.Hungary

14.Ireland

15.Italy

16.Latvia

17.Lithuania

18.Luxembourg

19.Malta

20.Netherlands

21.Poland

22.Portugal

23.Romania

24.Slovakia

25.Slovenia

26.Spain

27.Sweden

28.United Kingdom

 

Page 37 of 37

--------------------------------------------------------------------------------